–Organizational, social, or technical threats of blockchain
TITLE-ABSTR-KEY (distributed ledger technology OR DLT OR blockchain) AND TITLE-ABSTR-KEY (health* OR medical) AND TITLE-ABSTR-KEY (application OR scenario OR use case)
4.1.1 use case description..
Use case: patient-centric health data management | ||
---|---|---|
PHI: patient health information | ||
Access management | Enabling patients to authorize and revoke access to specific health information | : Interoperability [ ]; Use of smart contracts [ ]; Token support [ ] : Transaction content visibility [ ]; User unidentifiability [ ]; Node controller verification [ ]; : Compliance [ ] : Scalability [ ]; Resource consumption [ ]; Transaction validation latency [ ] : Ease of node setup [ ]; Ease of use [ ] : Authenticity [ ]; Availability [ ]; Confidentiality [ ]; Consistency [ ]; Fault tolerance [ ]; Integrity [ ]; Isolation [ ]; Strength of cryptography [ ] |
Secure record-keeping | Maintaining log files of activities within DLT-based applications for patient-centric health data management to prevent tampering | : Interoperability [ ]; Use of smart contracts [ ]; Token support [ ] : Transaction content visibility [ ]; User unidentifiability [ ]; Node controller verification [ ] : Compliance [ ] : Scalability [ ]; Resource consumption [ ] : Ease of use [ ] : Confidentiality [ ]; Integrity [ ]; Isolation [ ]; Strength of cryptography [ ]; |
Data sharing incentivization | Establishing a trustworthy and transparent environment to encourage patients to share their health data | : Interoperability [ ]; Use of smart contracts [ ] : Transaction content visibility [ ]; Node controller verification [ ] : Degree of decentralization [ ]; Incentive mechanism [ ] : Availability [ ]; Confidentiality [ ]; Integrity [ ] |
4.1.3 secure record-keeping., 4.1.4 data sharing incentivization., 4.2 management of electronic healthcare records (ehrs), 4.2.1 use case description..
Use case: management of EHRs | ||
---|---|---|
Access management | Controlling access permissions for EHRs | : Interoperability [ ]; Use of smart contracts [ ]; Token support [ ] : User unidentifiability [ ]; Node controller verification [ ] : Compliance [ ] : Resource consumption [ ]; Transaction validation latency [ ] : Ease of use [ ] : Authenticity [ ]; Availability [ ]; Confidentiality [ ]; Consistency [ ]; Integrity [ ]; Non-repudiation [ ] |
Secure record-keeping | Recording log files of operations on EHRs in a secure and transparent manner | : Interoperability [ ]; Use of smart contracts [ ] : User unidentifiability [ ]; Node controller verification [ ] : Scalability [ ]; Resource consumption [ ] : Ease of use [ ] : Authenticity [ ]; Availability [ ]; Confidentiality [ ]; Integrity [ ]; Non-repudiation [ ]; Strength of cryptography [ ] |
4.2.3 secure record-keeping., 4.3.1 use case description..
Use case: RPM | ||
---|---|---|
Access management | Controlling fine-grained access permissions over health data gathered by various remote devices | : Interoperability [ ]; Use of smart contracts [ ] : Transaction content visibility [ ]; User unidentifiability [ ]; Node controller verification [ ] : Compliance [ ]; Degree of decentralization [ ] : Scalability [ ]; Resource consumption [ ]; Throughput [ ]; Transaction validation latency [ ] : Transaction fee [ ] : Availability [ ]; Censorship resistance [ ]; Confidentiality [ ]; Fault tolerance [ ]; Integrity [ ]; Non-repudiation [ ]; Reliability [ ] |
Secure record-keeping | Timestamping and logging data transmissions with RPM accurately and securely | : Node controller verification [ ] : Compliance [ ]; Degree of decentralization [ ] : Scalability [ ]; Resource consumption [ ]; Throughput [ ]; Transaction validation latency [ ] : Transaction fee [ ] : Authenticity [ ]; Availability [ ]; Confidentiality [ ]; Integrity [ ]; Non-repudiation [ ] |
Process automation | Notifying of abnormal situations automatically for the timely detection of possible medical conditions | : Use of smart contracts [ ] : User unidentifiability [ ]; Node controller verification [ ] : Compliance [ ] : Scalability [ ]; Transaction validation latency [ ]; Authenticity [ ]; Strength of cryptography [ ] |
4.3.3 secure record-keeping., 4.3.4 process automation., 4.4 biomedical research, 4.4.1 use case description..
Use case: biomedical research | ||
---|---|---|
Access management | Defining and operating rules for access to research data and preventing study results from arbitrary manipulation | : Interoperability [ ]; smart contracts [ ] : Traceability [ ]; Transaction validation latency [ ]; User unidentifiability [ ]; Node controller verification [ ] : Integrity [ ] |
Secure record-keeping | Recording data gathered through research studies according to documentation requirements for biomedical research | : Traceability [ ]; Transaction validation latency [ ]; Node controller verification [ ] : Confidentiality [ ]; Integrity [ ] |
Data sharing incentivization | Incentivizing individuals to participate in research studies | : User unidentifiability [ ]; Node controller verification [ ] : Confidentiality [ ]; Integrity [ ] |
Process automation | Monitoring specific values (e.g., effects of a drug on participants) generated in biomedical research without manual checks | : Interoperability [ ]; Use of smart contracts [ ] : Node controller verification [ ] : Block creation interval [ ]; Throughput [ ] |
4.4.3 secure record-keeping., 4.4.4 data sharing incentivization., 4.4.5 process automation., 4.5 supply chain management (scm) for pharmaceutical drugs or medical devices, 4.5.1 use case description..
Use case: SCM for pharmaceutical drugs or medical devices | ||
---|---|---|
Secure record-keeping | Recording data generated during procurement, production, and delivery of pharmaceutical drugs or medical devices according to related regulations in an accurate manner | : Use of smart contracts [ ] : Transaction content visibility [ ]; Node controller verification [ ] : Compliance [ ] : Block size limit [ ]; Scalability [ ]; Throughput [ ]; Transaction validation latency [ ] : Ease of node setup [ ]; Ease of use [ ] : Authenticity [ ]; Availability [ ]; Integrity [ ] |
Process automation | (Partly) Automating negotiation and payment processes within the supply of pharmaceutical drugs or medical devices | : Use of smart contracts [ ] : Transaction content visibility [ ] : Availability [ ]; Confidentiality [ ]; Consistency [ ]; Integrity [ ]; Non-repudiation [ ] |
4.5.3 process automation., 4.6 contact tracing and warning for pandemics, 4.6.1 use case description..
Use case: contact tracing and warning for pandemics | ||
---|---|---|
Secure record- keeping | Storing individuals’ spatial movements, their infection status, and other related information for tracing their encounters with others | : Use of smart contracts [ ]; : Traceability [ ]; User unidentifiability [ ]; Node controller verification [ ] : Compliance [ ]; Degree of decentralization [ ] : Scalability [ ]; Transaction validation latency [ ]; Authenticity [ ]; Availability [ ]; Consistency [ ]; Integrity [ ] |
Process automation | Evaluating individuals’ movements and notifying them of potential infection risks based on their encounters | : Use of smart contracts [ ]; : Node controller verification [ ]; : Scalability [ ]; Transaction validation latency [ ] |
4.6.3 process automation., 5 discussion, 5.1 principal findings, 5.2 implications.
RQ | Key findings | Implications for research |
---|---|---|
RQ1 | —Six pertinent and two nascent DLT use cases in the health domain —Four general purposes of utilizing DLT in healthcare —While the basic idea of a purpose is consistent across use cases, there are use case-specific peculiarities | Our results reinforce the need for more contextualized research on and designs of DLT-based applications in healthcare. Especially researchers should consider and transparently report the domain-specific use case and the purpose for which they use DLT, when proposing, discussing, or evaluating DLT-based applications for healthcare. |
RQ2 | —30 DLT characteristics were proposed for DLT-based applications in the six pertinent use cases —Both use cases and purposes of utilizing DLT as well as their interplay can influence the requirements of DLT-based applications —The identified rationales provide a useful basis for explaining the suitability of specific DLT characteristics for a DLT-based application —Some DLT characteristics (e.g., auditability) are currently understudied | The identified rationales help to disentangle the concrete contributions of DLT to various use case-specific challenges in healthcare. Besides, the saturation of existing studies on DLT in healthcare in terms of some DLT characteristics is insufficient. Research on DLT in healthcare has a long way to go for a holistic picture of DLT-based applications. |
6 conclusion, a.1. dlt characteristics.
DLT Property | DLT Characteristics |
---|---|
—Interoperability | |
—Maintainability | |
—Use of Smart Contracts | |
—Token Support | |
—Transaction Payload | |
—Traceability | |
—Transaction Content Visibility | |
—User Unidentifiability | |
—Node Controller Verification | |
—Auditability | |
—Compliance | |
—Degree of Decentralization | |
—Incentive Mechanism | |
—Liability | |
—Block Creation Interval | |
—Block Size Limit | |
—Confirmation Latency | |
—Resource Consumption | |
—Propagation Delay | |
—Scalability | |
—Stale Block Rate | |
—Throughput | |
—Transaction Validation Latency | |
—Transaction Fee | |
—Ease of Node Setup | |
—Ease of Use | |
—Support for Constrained Devices | |
—Atomicity | |
—Authenticity | |
—Availability | |
—Censorship Resistance | |
—Confidentiality | |
—Consistency | |
—Durability | |
—Fault Tolerance | |
—Integrity | |
—Isolation | |
—Non-Repudiation | |
—Reliability | |
—Strength of Cryptography |
Applied computing
Life and medical sciences
Health care information systems
Software and its engineering
Software creation and management
Designing software
Trade-offs between distributed ledger technology characteristics.
When developing peer-to-peer applications on distributed ledger technology (DLT), a crucial decision is the selection of a suitable DLT design (e.g., Ethereum), because it is hard to change the underlying DLT design post hoc. To facilitate the selection ...
Blockchain has been increasingly used as a component to enable decentralisation in software architecture for a variety of applications. Blockchain governance has received considerable attention to ensure the safe and appropriate use ...
Blockchain in healthcare applications requires robust security and privacy mechanism for high-level authentication, interoperability and medical records sharing to comply with the strict legal requirements of the Health Insurance Portability and ...
Published in.
University of Pennsylvania, USA
William and Mary, USA
Association for Computing Machinery
New York, NY, United States
Check for updates, author tags.
Other metrics, bibliometrics, article metrics.
View or Download as a PDF file.
View online with eReader .
Check if you have access through your login credentials or your institution to get full access on this article.
Share this publication link.
Copying failed.
Affiliations, export citations.
We are preparing your search results for download ...
We will inform you here when the file is ready.
Your file of search results citations is now ready.
Your search export query has expired. Please try again.
You have full access to this open access article
255 Accesses
Explore all metrics
Global research has found that prevalence rates of child sexual abuse suggest that this is a significant ongoing public health concern. A recent Australian study, for example, revealed that more than three girls and almost one in five boys reported experiencing sexual abuse before the age of 18. Self-reported rates of abuse, however, far exceed official figures, suggesting that large numbers of children who experience sexual abuse do not come to the attention of relevant authorities. Whether and how those children have tried to tell their stories remains unclear.
The goal of the review was to explore scholarly literature to determine what was known about what enables or constrains children to disclose their experience of sexual abuse.
A systematic scoping review was undertaken to better understand the current state of knowledge in the scholarly literature on child sexual abuse disclosure. Thirty-two scholarly publications were included for analysis following a rigorous process of sourcing articles from five databases and systematically screening them based on transparent inclusion and exclusion criteria. Ecological systems and trauma-informed theoretical paradigms underpinned an inductive thematic analysis of the included manuscripts.
Three multi-dimensional themes were identified from the thirty-two publications. These themes were: factors enabling disclosure are multifaceted; barriers to disclosure include a complex interplay of individual, familial, contextual and cultural issues; and Indigenous victims and survivors, male survivors, and survivors with a minoritised cultural background may face additional barriers to disclosing their experiences of abuse.
The literature suggests that a greater understanding of the barriers to disclosures exists. Further research that supports a deeper understanding of the complex interplay of enablers and the barriers to disclosure across diverse populations is needed. In particular, future research should privilege the voices of victims and survivors of child sexual abuse, mobilising their lived experiences to co-create improved practice and policy.
Avoid common mistakes on your manuscript.
The prevalence of child sexual abuse is a matter of critical interest for researchers, policymakers and practitioners working with children, young people and their families. Worldwide estimates of child sexual abuse (CSA) prevalence are alarming, with an average of 18–20% of females and 8–10% of males reporting experiences of abuse (Pereda et al., 2009 ). A recent study in the USA, drawing from a sample of 2639 respondents aged 18–28, concluded that the overall prevalence rate of child sexual abuse was 21.7%. For females, this rate was found to be 31.6% and for males, 10.8% (Finkelhor et al., 2024 ). In Australia, the recently published Australian Child Maltreatment Study collected nationally representative data on rates of abuse and neglect and found that 37.3% of girls and 18.8% of boys had experienced child sexual abuse (Matthews et al., 2023 ).
Self-reported rates of abuse far exceed official figures, suggesting that large numbers of children who experience sexual abuse do not come to the attention of relevant authorities. As an example of the discrepancy between official statistics versus reports by survivors, offender conviction rates appear to be far lower than reported abuse. One study, for example, found that police did not lay charges in more than half of 659 cases where child sexual abuse was reported to them (Christensen et al., 2016 ). The two reasons provided were, first, insufficient evidence, and second, aspects of the child’s disclosure, particularly timing and detail, were inadequate for successful prosecution. In another example, a study based on an analysis of administrative data over a fourteen-year timeframe found that only one in five reported child sexual abuse matters proceeded further than the initial investigation phase. In this study, only 12% of reported offences resulted in a conviction, with the authors claiming that their findings were consistent with other studies (Cashmore et al., 2020 ). Further research to enable a better understanding of “how these (prosecution) decisions are made, over and above the characteristics of the complainant, suspect and type of offence” was recommended (Cashmore et al., 2020 , p. 93).
In another example, a meta-analysis that combined estimates of prevalence rates of child sexual abuse across 217 studies, then comparing these rates with official data from sources such as the police and child protection, found that analyses based on self-reports of victims and survivors revealed prevalence rates of up to 30 times greater than official reports (Stoltenborgh et al., 2015 ), indicating a sizeable gap between self-reported experiences of child sexual abuse by survivors and rates recorded by official authorities. Such a sizable gap suggests that further investigation into research that examines the process of disclosure is much needed, with a focus on what factors enable and constrain children and young people from talking about the abuse that they have experienced.
Child sexual abuse disclosure is theorised as a multifaceted, iterative and contextualised phenomenon that interacts directly or indirectly across a range of ecological variables. Both ecological (Bronfenbrenner., 1979 ) and trauma theories (Alaggia et al., 2019 ) consider a child victim within their context by considering the micro, meso and macro implications issues faced by children who have experienced the trauma of child sexual abuse.
In summary, the rationale for this review emerges from the child sexual abuse research literature, which reports very high prevalence rates of abuse, particularly where research participants are offered anonymity as young adults to recall their experiences (Finkelhor et al., 2024 ; Matthews et al., 2023 ). Evidence of these high rates of abuse, drawn from research, are not matched by official administrative data published in government reports, with research outcomes reporting on child sexual abuse prevalence up to 30 times greater than official statistics from relevant authorities (Stoltenborgh et al., 2015 ).
These issues raise serious and urgent questions about how children and young people who have experienced child sexual abuse are listened to, heard and responded to. Children and young people may raise their concerns in attempts to tell, only to meet with barriers that prevent them from feeling supported and safe.
This scoping review aimed to address that gap by examining the literature reporting on disclosures of child sexual abuse by examining the literature reporting on disclosures of child sexual abuse by considering the question: What do we know about what influences or enables children and young people to disclose their experience of child sexual abuse, and what are the barriers to disclosure?
Using the framework developed by Arksey and O’Malley ( 2005 ), a systematic scoping review methodology was used to identify the available research literature on the disclosure of child sexual abuse. To clarify the use of the term ‘systematic’ in the context of a scoping review, we adopted a methodologically sound process for searching the literature to scope the current state of knowledge concerning child sexual abuse disclosure (Allagia et al., 2019 ). The purpose of this review was to map the literature on child sexual abuse disclosure, identify key concepts that hinder or enable disclosure, and highlight gaps in the research. Scoping studies are particularly well-suited for complex topics, as they provide valuable insights for policymakers, practitioners, and future research (McPherson et al., 2019 ). Mapping the literature involved a five-stage sequential process as follows: developing a research question, systematically identifying potentially relevant studies, screening and selecting relevant studies based on identified inclusion and exclusion criteria, charting the data and collating, summarising and reporting the results (Arksey & O’Malley, 2005 , p. 8). This five-stage approach emphasises the importance of building a credible critique when investigating a largely unexplored topic (Munn et al., 2018 ).
This review took a multi-theoretical approach. Drawing on ecological systems and trauma-informed theoretical paradigms provided a robust framework for understanding the complex barriers to disclosing childhood sexual abuse. By integrating these two theories, we gained an understanding of how, at the individual level, trauma symptoms like shame, guilt, and fear can inhibit disclosure and, additionally, how relational dynamics (microsystems) and broader systemic and societal factors at the exo-system and macrosystem levels, can either support or hinder disclosure. CSA disclosure is often not a one-off event but rather a dynamic process reflecting the trauma of the abuse that may take place over time and can include incidents of retraction where survivors recant their stories (Alaggia et al., 2019 ). This phenomenon was first theorised by Roland Summit in 1983 and was revisited some decades later as child victims of abuse were reported to ‘accommodate’ abuse to the extent that disclosure was often delayed, conflicted and ultimately retracted (McPherson et al., 2017 ).
An ecological framework (Bronfenbrenner, 1979 ) considers a child contextually by taking into account the “ontogenic, micro-system, exo-system and macro-system” layers that inform childhood experiences (Alaggia, 2010 . p. 36). At the micro level, family dynamics can obstruct disclosure due to concerns about not being believed or feelings of loyalty to the abuser. In a different study, Alaggia ( 2004 ) points out that although children disclose in many different ways, the closer the familial relationship between the child and the perpetrator, the more difficult disclosure gets. CSA disclosure within a mesosystem encompasses the interactions among different components of the microsystem, such as churches, schools, and neighbourhoods, which can impede the disclosure process. In such interacting systems, the child who discloses can be placed in a liminal place, on the boundaries of the systems that the family is situated in, leading to demands for “compromise” for the “purposes of damage limitation” (Gardner, 2012 , p. 102). The exosystem, encompassing broader social systems like social services, can introduce complexities in the disclosure process due to inadequate reporting structures and limited interagency collaboration and resources for investigating child sexual abuse claims and frameworks of support to children who disclose. Gardner ( 2012 , p. 105) refers to these as “anxiety-provoking institutional dilemmas” wherein institutions respond with procedures that contain anxiety rather than through a trauma-informed practice of prioritising safety to reduce the risk of re-traumatisation. The macro-system envelopes the societal norms, laws, and policies, which influence the stigma and cultural taboos around child sexual abuse, potentially affecting how authorities or the adults in a child’s life respond to disclosures of child sexual abuse. Child sexual abuse disclosure is, therefore, a multifaceted, iterative and contextualised phenomenon that interacts directly or indirectly across all these ecological variables (Alaggia et al., 2019 ).
Phase one: developing the research question.
The following research question framed the systematic scoping review:
What do we know about what influences or enables children and young people to disclose their experience of child sexual abuse, and what are the barriers to disclosure?
A search strategy that aimed to identify peer-reviewed literature was developed. With the support of a research librarian, five electronic databases (InfoRMIT; Psychology and Behavioural Sciences Collection; APA PsycInfo; Academic Search Premier; ProQuest) were searched using a combination of carefully selected keywords: Child*ren, youth, AND Sexual Abuse OR Sexual Assault AND Disclosure OR Telling OR Sharing AND Barrier s OR Hindrance OR Facilitators OR Enablers . Searches were run from 2013 to (July) 2023.
Inclusion criteria The search was restricted to peer-reviewed academic journal articles published in English between 2013 and 2023. Articles focusing on what helped or hindered disclosure that helped to better understand children’s experience of disclosing were included. The inclusion criteria included both articles about children and young people (aged under 18) and articles about adults with lived experience of child sexual abuse who were recalling their experiences of disclosure.
Exclusion criteria Articles were excluded if published before 2013, were not published in a peer-reviewed scholarly journal or did not address the research question. Therefore, articles reporting rates and prevalence, prevention literature (unless it addressed responses to disclosure), diagnostic tools, practice frameworks, and legislative requirements were excluded. Non-English articles were also excluded due to the resources required for translation.
Grey literature was excluded due to quality, reliability, and publication bias concerns. Additionally, challenges in standardising and accessing globally available grey literature made it difficult to ensure evidence-based verification and reproducibility in the review (Mahood, 2014 ). Only peer-reviewed scholarly articles were included to maintain a systematic and transparent methodology.
Two researchers applied the inclusion and exclusion criteria to all the citations that the search strategy identified, continually reflecting on search strategies and methodological choices at each stage of sifting, charting and sorting (Arksey & O’Malley, 2005 ). Initial searches from the databases with the date, source and language criteria applied provided a list of 1625 publications. Titles were screened to ensure broad relevance to the research question and duplicates, with 1532 articles excluded. A review of abstracts was then undertaken for the remaining 93 articles, which led to a further 24 articles being removed.
Full-text articles (n = 69) were retrieved for those articles that had been included. Authors 1 and 4 examined these articles independently to decide if the articles confirmed the inclusion criteria. Author 2 resolved disagreement, resulting in 32 articles being included in the scoping review for inclusion in a thematic analysis. See Fig. 1 for the PRISMA that charts the screening process.
Prisma flow chart. Moher et al. ( 2009 )
Two researchers (Researchers 1 and 2) reviewed the selected thirty-two articles using Braun and Clarke’s ( 2021 ) ‘reflexive thematic analysis’ framework to code and identify emerging themes in the data. The six-phase process includes 1) data familiarisation and writing familiarisation notes; 2) systematic data coding; 3) generating initial themes from coded and collated data; 4) developing and reviewing themes; 5) refining, defining and naming themes; and 6) writing the report (Braun & Clarke, 2021 ).
As part of phase one, two researchers familiarised themselves with the data using a ‘descriptive-analytical’ method to consistently describe and categorise the key findings relevant to the research question, which formed the basis of the analysis (Arksey & O'Malley, 2005 ). Through this process, the researchers mapped the types, locations and key findings of included studies. The final set of 32 publications was collated and presented as a first-level analysis in Table 1 . There was no attempt to ‘weigh’ or assess the quality of each study as it is not the purpose of a scoping review, which seeks to present an overview of the material reviewed and, consequently, enable the identification of gaps in existing literature (Arksey & O'Malley, 2005 , p. 17).
In phases 2 and 3, the two researchers began reviewing and generating initial codes to “identify and make sense of patterns of meaning across a dataset” (Braun & Clarke, 2021 , p. 331) before organising the data thematically using the database program Excel. In phases 4 and 5, the researchers continued to refine and develop themes, encompassing the reflexive qualitative skills of the researchers as analytic resources. The themes were reviewed carefully together and independently by the broader research team to evolve the analysis, an “analytic process involving immersion in the data, reading, reflecting, questioning, imagining, wondering, writing, retreating, returning.” (Braun & Clarke, 2021 , p. 332).
The researchers undertook reflexive consultation together and independently to enhance the overall research process. This critical process involved two researchers screening, charting, and collating data. By incorporating this reflexive consultative approach, the researchers ensured they continually reflected on search strategies and methodological choices. This method is not linear but iterative and requires the researchers to engage with each stage of the scoping review reflexively (Arksey & O’Malley, 2005 ).
The researchers “made sense of” the data by summarising and interpreting key themes, patterns, and gaps using various frameworks, including a ‘descriptive-analysis’ (Arksey & O’Malley, 2005 ) and ‘reflexive thematic analysis’ (Braun & Clarke, 2021 ). Preliminary themes and findings were then developed, reported and refined with the broader research team of eight academic researchers and practitioners as subject matter experts to gather their insights, perspectives, and feedback on the preliminary findings. Using a ‘reflexive thematic analysis’ to gather insights, perspectives, and feedback, the researchers enhanced and evolved understandings of child sexual abuse disclosure (Braun & Clarke, 2021 ). This ‘consultation exercise’ is supported by other researchers who have recognised the value of consultation in enriching and confirming research outcomes (Oliver, 2001 ).
Following the research team's engagement with the ‘reflexive thematic analysis’ process in the analysis phase, the researchers continued to workshop emergent themes concerning the research question and theoretical framework. Three core themes were identified in the analyses of the 32 articles: (i) Factors enabling disclosure are multifaceted; (ii) Barriers to disclosure include a complex interplay of individual, familial, contextual and cultural issues; (iii) Indigenous victims and survivors, male survivors and survivors with a minoritised cultural background may face additional barriers to disclosing their experiences of abuse.
A summary of the multifaceted barriers and enablers impacting the disclosure of child sexual abuse across various domains is presented below in Table 2 .
Within each theme, these factors are discussed below using a social-ecological and reflexive critical theoretical lens.
While most research in this review identified barriers to disclosure, some enabling influences were also identified. Disclosure is conceptualised as a process rather than a one-time event (Tat & Ozturk, 2019 ) that can be affected by personal (individual), interpersonal (mutual or related) and societal (socio-political) factors (Easton et al., 2014 ; Ullman, 2023 ). For example, strong personal factors that influence disclosure may be the desire to protect oneself and prevent further abuse, seek support, clarification, and validation, unburden themselves, seek justice, and document the abuse. (Easton et al., 2014 ; Kasstan, 2022 ; Lusky-Weisrose et al., 2022 ; Ullman, 2023 ). Often, the likelihood of disclosing increases with age (Wallis & Woodworth, 2020 ).
A trusted and supportive individual, such as a parent, friend, teacher, or counsellor, is a significant interpersonal factor that encourages disclosure. The perception of protectiveness and safety from ‘trusted adults’ is crucial, particularly from mothers, who are often recipients of disclosure (Russell & Higgins, 2023 ). According to Rakovec-Felser and Vidovič ( 2016 ), this is especially important for female child victims of sexual abuse. These researchers found that those with safe and supportive mothers needed about nine months to disclose the abuse, whereas those without such support took approximately 6.9 years to disclose.
Having safe or ‘trusted adults’ also appeared in other research as an enabler of what helps children to ‘tell’ or disclose instances of abuse or CSA-related concerns (Russell & Higgins, 2023 ). However, an important finding was that disclosures to ‘trusted adults’ primarily occurred when the perpetrator was also an adult. In instances when the perpetrators of CSA were peers, children and young people were less likely to ‘tell’ adults, professionals, or organisations and more likely to ‘tell’ a friend (Russell & Higgins, 2023 ).
Societal or environmental factors that enable disclosure were linked to ‘memorable life events’ by Allnock ( 2017 ). These events are significant moments that can change one's life, which Allnock ( 2017 ) calls ‘turning points’, critical moments where survivors feel motivated to disclose their experiences. Turning points could occur accidentally following discussions, conversations, or watching television programs where sexual abuse appeared as a theme, enabling awareness of abusive behaviours and acting as a catalyst to tell (Allnock, 2017 ). Turning points could also represent the escalation of the offender’s behaviour, survivors becoming aware of other victims, or interventions by police investigations or child protection that may mutually ‘help others’ (Ullman, 2023 ).
Reflecting previous research, barriers to disclosure were found to outweigh facilitators of disclosure and tend to be multifaceted (Collin-Vézina et al., 2015 ; Easton et al., 2014 ). Barriers involve a complex interplay of individual, familial, contextual, and cultural issues, with age and gender predictive of delayed disclosure for younger children and adolescents (Sivagurunathan et al., 2019 ).
Multiple studies identified barriers across three broad domains, including personal (internal) barriers, which may include not identifying the experience as sexual abuse, and internal emotions such as shame, self-blame, fear and hopelessness (Collin-Vézina et al., 2015 ; Devgun et al., 2021 ; Easton, 2013 ) or the ‘the normality/ambiguity of the situation’ (Wager, 2015 ). Young children, particularly preschoolers, often have specific fears and barriers to telling or disclosing even when asked by professionals, as they might not understand the purpose of the interview, the crime they have been victim to, or the consequences of disclosing (Magnusson et al., 2017 ). Interpersonal barriers, including dynamics with the perpetrator, the relationship between the perpetrator and family, and the fear of consequences or negative self-representation, were found to impact disclosure significantly (Allnock, 2017 ; Collin-Vézina et al., 2015 ; Devgun et al., 2021 ; Easton, 2013 ; Gemara & Katz, 2023 ; Gruenfeld et al., 2017 ; Halvorsen et al., 2020 ; Wager, 2015 ).
Social or environmental barriers including limited social networks, a lack of opportunities or access to safe adults to disclose to can also lead to disclosures being downplayed or ignored by those who received them, often reinforcing internalised victim-blaming (Collin-Vézina et al., 2015 ). These barriers may include social and cultural norms related to sex, misconceptions and stereotypes about child sexual abuse survivors and perpetrators, and a lack of viable services to respond to disclosures (Collin-Vézina et al., 2015 ; Devgun et al., 2021 ; Easton, 2013 ; Mooney, 2021 ). In fact, according to Easton ( 2013 ) and Marmor ( 2023 ), many survivors who disclosed their experiences of CSA were unable to receive help despite their disclosures. In some cases, the mishandling of disclosures by law enforcement officers, child protection specialists, medical staff, and mental health professionals also created further barriers to disclosing from a sense of hopelessness (Pacheco et al., 2023 ; Wager, 2015 ). Furthermore, a range of context-specific issues were identified in the literature as barriers to disclosure. These included the impact of colonisation, cultural issues, and gender, which are discussed below.
Some authors highlighted the ongoing legacy of colonial violence as a personal and structural barrier to the disclosure of child sexual abuse (Braithwaite, 2018 ; Tolliday, 2016 ). For Australian First Nations Peoples who were victims and survivors, “child sexual abuse in Aboriginal and Torres Strait Islander communities is a complex issue that cannot be understood in isolation from the ongoing impacts of colonial invasion, genocide, assimilation, institutionalised racism, and severe socio-economic deprivation. Service responses to child sexual abuse are often experienced as racist, culturally, financially, and/or geographically inaccessible” (Funston, 2013 , p. 381). Consistent with these findings, Tolliday ( 2016 ) examines historical efforts to address sexual safety for Aboriginal and Torres Strait Islander women and children, concluding that these problems cannot be resolved unless the underlying trauma experienced by First Nations Peoples is attended to. An additional barrier for Australian First Nations Peoples may be a level of mistrust in authorities such as police and child protection services, who were found to be involved in the forced removal of Aboriginal and Torres Strait Islander children from their families (Human Rights & Equal Opportunity Commission, 1997 ).
In investigating delayed disclosure, Braithwaite ( 2018 ) found that for rural Alaskan Native survivors, the impact of colonisation may be a significant barrier to survivors disclosing abuse. The inability to trust authorities directly results from colonisation and systemic, intergenerational poverty, where disclosing abuse may negatively impact already impoverished families.
In reporting on these issues, it is important not to present child sexual abuse as an inherent racial, religious, or cultural concern. As Taylor and Norma ( 2013 ) argue, describing interpersonal barriers for women of culturally or racially diverse backgrounds in Australia to disclose childhood sexual abuse has often been described as “cultural”, but it is more a “familial culture” rather than an aspect of ethnic culture, wherein barriers to reporting sexual abuse are from wanting to protect their family and community from shame, stigma, or loss of dignity in a society where a community as a whole can be racially and culturally vilified for the actions of a few offenders.
In other contexts, researchers found that “familial culture” barriers were experienced by many survivors in other highly racialized contexts. For example, researchers found that in South Africa, the desire for families to preserve the dignity of the family and avoid shame in the community may have inhibited children from wanting to disclose sexual abuse, consequently prioritising the reputation of the family over disclosure (Ramphabana et al., 2019 ). Likewise, in East Asian communities in Canada, the concern that such a negative incident can ruin the family and the victim’s reputation and damage relationships with other community members can also dissuade disclosure from children and reporting from their families (Roberts et al., 2016 ). When living within cultural norms that promote self-scrutiny, children feel responsible for their actions and may blame themselves for the abuse or for the impacts of disclosing (Roberts et al., 2016 ).
Fear of family disruption or breaking up the family, including placement in foster care or the criminal justice system (Allnock, 2017 ), were also mentioned as barriers to disclosure. This was found particularly in contexts where perpetrators contribute financially to the family or are the breadwinners upon whom the children rely for survival. These fears may be compounded within cultures enshrined within strong patriarchal values, where male dominance over women and children is normalised or socially accepted. This has been witnessed in East Asian communities in Canada, which are greatly influenced by Confucian philosophy and patriarchal lineage and where societal and familial harmony is expected to outweigh personal needs. Taken together, this could contribute significantly to the low reporting rate of Asian child sexual abuse, which is disproportionate to that of Caucasian children in Canada (Roberts et al., 2016 ). Other factors for low disclosure are linked to fears of condemnation or desire to protect parents, family, and community from reprisal, including, in extreme circumstances, fear of ostracization, death threats, honour killings (Marmor, 2023 ), physical violence, the risk of being disowned by family or expelled from school, discrimination, isolation from social networks, and emotional abuse within the community (Obong'o et al., 2020 ). For already vulnerable, minoritised communities, this creates a double layer of vulnerability in broader society.
How a community views sex can also make it difficult for children, families, and communities to identify and disclose child sexual abuse, particularly in sexually conservative, religious-cultural contexts where sex may be taboo, stigmatising, or disrespectful to discuss with children (Ramphabana et al., 2019 ). In a study from Zimbabwe, stigma and discrimination from being labelled as having sexually transmitted diseases or for losing their virginity were expressed as a fear of disclosure (Obong'o et al., 2020 ). There are also religious prohibitions against reporting sexual abuse or violence to secular authorities (Marmor, 2023 ), as this would tarnish the religious image in secular contexts. This suggests that the emphasis on purity culture, silencing of discussions on sexuality, diminished reporting due to fear of the influence of secular values, and reliance on disclosing to religious authority figures rather than professionals act as religious and cultural barriers to reporting child sexual abuse (Lusky-Weisrose et al., 2022 ). When combined, it reduces survivors’ ability to identify and disclose child sexual abuse alongside institutional barriers and adds layers of possible isolation in cultural contexts that also serve as social protection for minoritised groups.
The role of gender in child sexual abuse disclosure was identified as a noteworthy barrier. Researchers highlight the difference in disclosure patterns of male child sexual abuse survivors, which tend to be delayed for years or even decades compared to female survivors, and some male survivors were found to have lower rates of ever disclosing the abuse (Easton, 2013 ; Easton et al., 2014 ). Like many survivors of child sexual abuse, male survivors feared not being believed, justifiably, as historically there was a lack of awareness of the existence of male child sexual abuse, despite researchers finding that approximately 15% of adult men report being sexually abused during childhood (Easton et al., 2014 ). The mass media coverage of institutional abuse scandals, such as those at the Catholic Church, Boy Scouts of America, and Penn State University, have now raised public awareness of the sexual abuse of boys and how the impacts of child sexual abuse, such as deep-seated rage, shame, spiritual distress, and stigma (Easton, 2013 ) have influenced delayed or non-disclosure.
Gendered societal norms also strongly influence individual, group, and societal ideas and behaviours towards male sexual abuse (Sivagurunathan et al., 2019 ). These include, notably, ideas of male gender identity, masculinity, and masculine norms such as winning, emotional control, homophobia, and self-reliance, including negative attitudes towards victimhood and help-seeking. Additionally, as boys are often sexually abused by other males, many survivors fear the stigma of being labelled homosexual (Easton, 2013 ; Easton et al., 2014 ). Some survivors who self-identified as gay or bisexual also feared that others would use their abuse to explain their sexual orientation, saying it “made me gay” (Easton, 2013 ; Easton et al., 2014 ). Other survivors also questioned their sexual orientation due to their abuse experiences, blamed themselves, or feared being seen by others as having unconsciously invited the abuse (Sivagurunathan et al., 2019 ).
External barriers to disclosure were also identified regarding child protection workers, law enforcement, and clinicians (Easton, 2013 ), as well as religious institutions, such as churches and mosques, who were also found to have obstructed the identification and treatment of child sexual abuse in males due to societal attitudes about sex and the stigma of child sexual abuse. Additionally, there is a double standard when it comes to how sexual abuse among men is framed in mainstream media in a society that tends to glorify the sexual abuse of male children as a sexual initiation or sexual prowess if the perpetrator is an older woman. These double standards may, in turn, result in the further reluctance of male child sexual abuse survivors to disclose such experiences (Sivagurunathan et al., 2019 ), which is part of the reason why the helpfulness of responses to child sexual abuse disclosure across a male survivor’s lifespan is mixed (Easton, 2013 ). Combined, they all link to larger societal issues around gendered social expectations and how they impact child sexual abuse disclosure. If hegemonic masculinity and the conforming of traditional gendered roles lead to delayed disclosure or not disclosing at all for male survivors, a question arises concerning the child sexual abuse experiences of transgender and gender-diverse people, who are disproportionately affected by prejudice-motivated discrimination and violence.
Thirty-two manuscripts were reviewed to respond to the question: What is known about what influences or enables children and young people to disclose their experience of child sexual abuse, and what are the barriers to disclosure?
This review found that a significant enabler for disclosure is the presence of a safe relationship. This finding is consistent with emerging knowledge about the impact of trauma, which suggests that children may first choose to disclose to a friend or person they trust. Another clear finding in the literature is that disclosure should not be conceptualised as a single event at a point in time. Disclosure is seen as multifaceted, contextual and likely to be iterative, taking place over time. This raises critical questions about the extent to which legislative, policy and practice frameworks are sensitised to this finding.
These findings should contribute to the design of policies that support practices enabling children to experience safe spaces and relationships within which they may feel able to disclose, in their own time, the abuse that they have experienced. Services designed to engage and support all children and young people, including schools, sports and recreation facilities, should give attention to various strategies to promote a sense of safety for their child participants. These services should be accompanied by clearly articulated policies to support children and young people through the process of disclosure. In addition, services designed to respond to child victims, such as statutory child protection and police, must be designed with children in mind. In practice, adult-centric forensic models of interviews conducted by police and child protection may be premised on a single contact with the child. This approach may not match the child’s need to reveal details of their experience over time in what we know to be an often iterative process. All children’s services should become familiar with the behavioural indicators that some children, particularly younger children, may demonstrate rather than using words to disclose.
The notable research gaps are of importance for future research. For example, critical questions are raised concerning the lack of studies on diverse cohorts, including LGBTQIA + survivors, Indigenous survivors or survivors living with a disability. Whilst the prevailing research does address the facilitators of disclosure to an extent, the volume of literature reporting on the barriers to disclosure is greater. A more in-depth understanding by policymakers, practitioners and researchers of some of the obstacles, including broader social and sociocultural barriers, is needed.
Further research to hear from a diverse cohort of survivors to explore their experiences of disclosing child sexual abuse is urgently needed. Overall, this review highlights the need to advance the understanding of the processes of child sexual abuse across diverse cohorts and contexts to improve service systems’ capacity to listen, hear, and respond appropriately to children and young people.
Overall, this review highlights the need to advance the understanding of the processes of child sexual abuse across diverse cohorts and contexts to improve service systems’ capacity to listen, hear, and respond appropriately to children and young people.
Several methodological limitations apply to this analysis. This review has not identified all relevant literature due to the scope of databases searched and the likelihood that not all contemporary search terms were utilised, which might limit the comprehensiveness of the review. The research question sought information about disclosures of child sexual abuse; however, many practice responses to disclosure are likely unpublished in scholarly journals. As grey literature was excluded, potentially valuable insights from reports, theses, conference papers, and other non-peer-reviewed sources were not considered. This limitation is compounded by the inherent difficulty in drawing generalisable conclusions from scoping reviews, which encompass a variety of methodologies, populations, and contexts.
Another limitation is that only articles published in English were included, potentially resulting in the exclusion of crucial studies published in other languages. Additionally, the reliance on peer-reviewed journals may introduce publication bias, as studies with significant or positive results from the UK or North America are more likely to be published. There is also the possibility of subjective bias, as the identification and interpretation of themes depend on the researchers' perspectives.
Furthermore, as it is not within the remit of a scoping review to assess the quality of included studies, findings from lower-quality studies are considered alongside those from higher-quality studies without differentiation. However, the choice to include and conduct scholarly literature that undergoes independent double-blind peer review was made to reduce quality and publication bias risks.
Rather than simply being a one-off event, the disclosure of child sexual abuse is often a complex and ongoing process (Alaggia et al., 2019 ). More is known about barriers than enablers to disclosure, with barriers dominating the published literature sourced in this review. It is evident that, for children and young people, talking about the abuse that they have endured can be overwhelmingly challenging for them across personal, interpersonal and broader levels.
When children and young people begin to disclose, this review raised critical questions about how service systems respond to initial disclosure, particularly the extent to which policies and systems are designed to reflect children’s best interests.
Adults noticing when children and young people are distressed helps victims and survivors to disclose, as does creating trusting relationships to provide opportunities to tell their stories (Russell et al., 2023 ). To whom children elect to disclose is an important question, with recent research suggesting that when children and young people feel unsafe, they are more likely to tell a friend than an adult (Russell et al., 2023 ). Research is urgently required to develop a more robust understanding of the enablers of disclosure across diverse populations. This research needs to privilege the voices of victims and survivors with lived and living experiences of child sexual abuse.
Alaggia, R. (2004). Many ways of telling: Expanding conceptualizations of child sexual abuse disclosure. Child Abuse & Neglect, 28 (11), 1213–1227. https://doi.org/10.1016/j.chiabu.2004.03.016
Article Google Scholar
Alaggia, R. (2010). An ecological analysis of child sexual abuse disclosure: Considerations for child and adolescent mental health. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 19 (1), 32–39.
PubMed PubMed Central Google Scholar
Alaggia, R., Collin-Vézina, D., & Lateef, R. (2019). Facilitators and barriers to child sexual abuse (CSA) disclosures: A research update (2000–2016). Trauma, Violence, & Abuse, 20 (2), 260–283. https://doi.org/10.1177/1524838017697312
*Allnock, D. S. (2017). Memorable life events and disclosure of child sexual abuse: Possibilities and challenges across diverse contexts. Families, Relationships and Societies, 6 (2), 185–200. https://doi.org/10.1332/204674317X14866455118142
Arksey, H., & O’Malley, L. (2005). Scoping studies: Towards a methodological framework. International Journal of Social Research Methodology, 8 (1), 19–32. https://doi.org/10.1080/1364557032000119616
*Braithwaite, J. (2018). Colonized silence: Confronting the colonial link in rural Alaska native survivors’ non-disclosure of child sexual abuse. Journal of Child Sexual Abuse, 27 (6), 589–611. https://doi.org/10.1080/10538712.2018.1491914
Article PubMed Google Scholar
Braun, V., & Clarke, V. (2021). One size fits all? What counts as quality practice in (reflexive) thematic analysis? Qualitative Research in Psychology, 18 (3), 328–352. https://doi.org/10.1080/14780887.2020.1769238
Bronfenbrenner, U. (1979). Reality and research in the ecology of human development. Proceedings of the American Philosophical Society, 119 (6), 439–469.
Google Scholar
Cashmore, J., Taylor, A., & Parkinson, P. (2020). Fourteen-year trends in the criminal justice response to child sexual abuse reports in New South Wales. Child Maltreatment, 25 (1), 85–95. https://doi.org/10.1177/1077559519853042
Christensen, L. S., Sharman, S. J., & Powell, M. B. (2016). Identifying the characteristics of child sexual abuse cases associated with the child or child’s parents withdrawing the complaint. Child Abuse & Neglect, 57 , 53–60. https://doi.org/10.1016/j.chiabu.2016.05.004
*Collin-Vézina, D., De La Sablonnière-Griffin, M., Palmer, A. M., & Milne, L. (2015). A preliminary mapping of individual, relational, and social factors that impede disclosure of childhood sexual abuse. Child Abuse & Neglect, 43 , 123–134. https://doi.org/10.1016/j.chiabu.2015.03.010
*Devgun, M., Roopesh, B. N., & Seshadri, S. (2021). Breaking the silence: Development of a qualitative measure for inquiry of child sexual abuse (CSA) awareness and perceived barriers to CSA disclosure. Asian Journal of Psychiatry, 57 , 102558–102558. https://doi.org/10.1016/j.ajp.2021.102558
*Easton, S. D. (2013). Disclosure of child sexual abuse among adult male survivors. Clinical Social Work Journal, 41 (4), 344–355. https://doi.org/10.1007/s10615-012-0420-3
*Easton, S. D., Saltzman, L. Y., & Willis, D. G. (2014). “Would you tell under circumstances like that?”: Barriers to disclosure of child sexual abuse for men. Psychology of Men & Masculinity, 15 (4), 460–469. https://doi.org/10.1037/a0034223
Finkelhor, D., Turner, H., & Colburn, D. (2024). The prevalence of child sexual abuse with online sexual abuse added. Child Abuse & Neglect, 149 , 106634. https://doi.org/10.1016/j.chiabu.2024.106634
*Funston, L. (2013). Aboriginal and Torres Strait Islander worldviews and cultural safety transforming sexual assault service provision for children and young people. International Journal of Environmental Research and Public Health, 10 (9), 3818–3833. https://doi.org/10.3390/ijerph10093818
Article PubMed PubMed Central Google Scholar
Gardner, F. (2012). Defensive processes and deception: An analysis of the response of the institutional church to disclosures of child sexual abuse. British Journal of Psychotherapy, 28 (1), 98–109. https://doi.org/10.1111/j.1752-0118.2011.01255.x
Gemara, N., & Katz, C. (2023). “It was really hard for me to tell”: The gap between the child’s difficulty in disclosing sexual abuse, and their perception of the disclosure recipient’s response. Journal of Interpersonal Violence, 38 (1–2), 2068–2091. https://doi.org/10.1177/08862605221099949
*Gruenfeld, E., Willis, D. G., & Easton, S. D. (2017). “A very steep climb”: Therapists’ perspectives on barriers to disclosure of child sexual abuse experiences for men. Journal of Child Sexual Abuse, 26 (6), 731–751. https://doi.org/10.1080/10538712.2017.1332704
*Halvorsen, J. E., Tvedt Solberg, E., & Hjelen Stige, S. (2020). “To say it out loud is to kill your own childhood: an exploration of the first person perspective of barriers to disclosing child sexual abuse. Children and Youth Services Review, 113 , 104999. https://doi.org/10.1016/j.childyouth.2020.104999
Human Rights and Equal Opportunity Commission. (1997). Bringing them home: Inquiry into the separation of indigenous children from their families . Human Rights and Equal Opportunity Commission.
*Kasstan, B. (2022). everyone’s accountable? Peer sexual abuse in religious schools, digital revelations, and denominational contests over protection. Religions (Basel), 13 (6), 556. https://doi.org/10.3390/rel13060556
*Lusky-Weisrose, E., Fleishman, T., & Tener, D. (2022). “A little bit of light dispels a lot of darkness”: online disclosure of child sexual abuse by authority figures in the Ultraorthodox Jewish community in Israel. Journal of Interpersonal Violence, 37 , NP17758–NP17783. https://doi.org/10.1177/08862605211028370
*Magnusson, M., Ernberg, E., & Landström, S. (2017). Preschoolers’ disclosures of child sexual abuse: Examining corroborated cases from Swedish courts. Child Abuse & Neglect, 70 , 199–209. https://doi.org/10.1016/j.chiabu.2017.05.018
Mahood, Q., Eerd, D. V., & Irvin, E. (2014). Searching for grey literature for systematic reviews: Challenges and benefits. Research Synthesis Methods, 5 (3), 221–234. https://doi.org/10.1002/jrsm.1106
*Marmor, A. (2023). “I never said anything. I didn’t tell anyone. What would I tell?” Adults’ perspectives on disclosing childhood sibling sexual behavior and abuse in the Orthodox Jewish communities. Journal of Interpersonal Violence, 38 , 10839–10864. https://doi.org/10.1177/08862605231175906
Mathews, B., Pacella, R., Scott, J. G., Finkelhor, D., Meinck, F., Higgins, D. J., Erskine, H. E., Thomas, H. J., Lawrence, D. M., Haslam, D. M., Malacova, E., & Dunne, M. P. (2023). The prevalence of child maltreatment in Australia: Findings from a national survey. Medical Journal of Australia, 218 (S6), S13–S18. https://doi.org/10.5694/mja2.51873
McPherson, L., Gatwiri, K., Cameron, N., & Parmenter, N. (2019). The evidence base for therapeutic group care: a systematic scoping review. Centre for excellence in therapeutic care. https://www.cetc.org.au/the-evidence-base-for-therapeutic-group-care-a-systematic-scoping-review-research-brief/
McPherson, L., Long, M., Nicholson, M., Cameron, N., Atkins, P., & Morris, M. E. (2017). Secrecy surrounding the physical abuse of child athletes in Australia. Australian Social Work, 70 (1), 42–53. https://doi.org/10.1080/0312407X.2016.1142589
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement: e1000097. PLoS Medicine . https://doi.org/10.1371/journal.pmed.1000097
*Mooney, J. (2021). How adults tell: a study of adults’ experiences of disclosure to child protection social work services. Child Abuse Review, 30 (3), 193–209. https://doi.org/10.1002/car.2677
Munn, Z., Peters, M. D. J., Stern, C., Tufanaru, C., McArthur, A., & Aromataris, E. (2018). Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Medical Research Methodology, 18 (1), 143–143. https://doi.org/10.1186/s12874-018-0611-x
*Obong’o, C. O., Patel, S. N., Cain, M., Kasese, C., Mupambireyi, Z., Bangani, Z., Pichon, L. C., & Miller, K. S. (2020). Suffering whether you tell or don’t tell: Perceived re-victimization as a barrier to disclosing child sexual abuse in Zimbabwe. Journal of Child Sexual Abuse, 29 (8), 944–964. https://doi.org/10.1080/10538712.2020.1832176
Oliver, S. (2001). Marking research more useful: integrating different perspectives and different methods. In S. Oliver & G. Peersman (Eds.), Using research for effective health promotion (pp. 167–179). Open University Press.
*Pacheco, E. L. M., Buenaventura, A. E., & Miles, G. M. (2023). “She was willing to send me there”: Intrafamilial child sexual abuse, exploitation and trafficking of boys. Child Abuse & Neglect, 142 (Pt 2), 105849–105849. https://doi.org/10.1016/j.chiabu.2022.105849
Pereda, N., Guilera, G., Forns, M., & Gómez-Benito, J. (2009). The international epidemiology of child sexual abuse: A continuation of Finkelhor (1994). Child Abuse & Neglect, 33 (6), 331–342. https://doi.org/10.1016/j.chiabu.2008.07.007
*Rakovec-Felser, Z., & Vidovič, L. (2016). Maternal perceptions of and responses to child sexual abuse. Zdravstveno Varstvo, 55 (2), 1–7. https://doi.org/10.1515/sjph-2016-0017
*Ramphabana, L. B., Rapholo, S. F., & Makhubele, J. C. (2019). The influence of socio-cultural practices amongst Vhavenda towards the disclosure of child sexual abuse: Implications for practice. Gender & Behaviour, 17 (4), 13948–13961.
*Roberts, K. P., Qi, H., & Zhang, H. H. (2016). Challenges facing East Asian immigrant children in sexual abuse cases. Canadian Psychology Psychologie = Canadienne, 57 (4), 300–307. https://doi.org/10.1037/cap0000066
*Romano, E., Moorman, J., Ressel, M., & Lyons, J. (2019). Men with childhood sexual abuse histories: Disclosure experiences and links with mental health. Child Abuse & Neglect, 89 , 212–224. https://doi.org/10.1016/j.chiabu.2018.12.010
*Rothman, E. F., Bazzi, A. R., & Bair-Merritt, M. (2015). “I’ll do whatever as long as you keep telling me that I’m important”: a case study illustrating the link between adolescent dating violence and sex trafficking victimization. The Journal of Applied Research on Children . https://doi.org/10.58464/2155-5834.1238
*Russell, D. H., & Higgins, D. J. (2023). Friends and safeguarding: Young people’s views about safety and to whom they would share safety concerns. Child Abuse Review, 32 (3), e2825. https://doi.org/10.1002/car.2825
*Sivagurunathan, M., Orchard, T., MacDermid, J. C., & Evans, M. (2019). Barriers and facilitators affecting self-disclosure among male survivors of child sexual abuse: The service providers’ perspective. Child Abuse & Neglect, 88 , 455–465. https://doi.org/10.1016/j.chiabu.2018.08.015
Stoltenborgh, M., Bakermans-Kranenburg, M. J., Alink, L. R. A., & van Ijzendoorn, M. H. (2015). The prevalence of child maltreatment across the globe: Review of a series of meta-analyses. Child Abuse Review, 24 (1), 37–50. https://doi.org/10.1002/car.2353
Summit, R. C. (1983). The child sexual abuse accommodation syndrome. Child Abuse & Neglect, 7 (2), 177–193. https://doi.org/10.1016/0145-2134(83)90070-4
*Swain, S. (2015). Giving voice to narratives of institutional sex abuse. The Australian Feminist Law Journal, 41 (2), 289–304. https://doi.org/10.1080/13200968.2015.1077554
*Tat, M. C., & Ozturk, A. (2019). Ecological system model approach to self-disclosure process in child sexual abuse. Current Approaches to Psychiatry, 11 (3), 363–386. https://doi.org/10.18863/pgy.455511
*Taylor, S. C., & Norma, C. (2013). The ties that bind: Family barriers for adult women seeking to report childhood sexual assault in Australia. Women’s Studies International Forum, 37 , 114–124. https://doi.org/10.1016/j.wsif.2012.11.004
*Tolliday, D. (2016). “Until we talk about everything, everything we talk about is just whistling into the wind”: An interview with Pam Greer and Sigrid (‘Sig’) Herring. Sexual Abuse in Australia and New Zealand, 7 (1), 70–80.
*Ullman, S. E. (2023). Facilitators of sexual assault disclosure: A dyadic study of female survivors and their informal supports. Journal of Child Sexual Abuse, 32 (5), 615–636. https://doi.org/10.1080/10538712.2023.2217812
*Wager, N. M. (2015). Understanding children’s non-disclosure of child sexual assault: Implications for assisting parents and teachers to become effective guardians. Safer Communities, 14 (1), 16–26. https://doi.org/10.1108/SC-03-2015-0009
*Wallis, C. R. D., & Woodworth, M. D. (2020). Child sexual abuse: An examination of individual and abuse characteristics that may impact delays of disclosure. Child Abuse & Neglect, 107 , 104604–104604. https://doi.org/10.1016/j.chiabu.2020.104604
*Weiss, K. G. (2013). “You just don’t report that kind of stuff”: Investigating teens’ ambivalence toward peer-perpetrated, unwanted sexual incidents. Violence and Victims, 28 (2), 288–302. https://doi.org/10.1891/0886-6708.11-061
Download references
This project was funded by the National Centre for Action on Child Sexual Abuse. The findings and views reported within are those of the authors.
Open Access funding enabled and organized by CAUL and its Member Institutions.
Authors and affiliations.
Faculty of Health, Centre for Children and Young People, Southern Cross University, Locked Mail Bag 4, Coolangatta, QLD, 4225, Australia
Lynne McPherson, Kathomi Gatwiri, Anne Graham, Kelly Hand & Samara James
Gnibi College of Australian Indigenous Peoples, Southern Cross University, Lismore, Australia
Darlene Rotumah
Department of Rural Allied Health, La Trobe University, Shepparton, Australia
Corina Modderman
Centre Against Violence, Wangaratta, Australia
Jaime Chubb
You can also search for this author in PubMed Google Scholar
Correspondence to Lynne McPherson .
Conflict of interest, additional information, publisher's note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ .
Reprints and permissions
McPherson, L., Gatwiri, K., Graham, A. et al. What Helps Children and Young People to Disclose their Experience of Sexual Abuse and What Gets in the Way? A Systematic Scoping Review. Child Youth Care Forum (2024). https://doi.org/10.1007/s10566-024-09825-5
Download citation
Accepted : 08 September 2024
Published : 18 September 2024
DOI : https://doi.org/10.1007/s10566-024-09825-5
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess .
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
Find support for a specific problem in the support section of our website.
Please let us know what you think of our products and services.
Visit our dedicated information section to learn more about MDPI.
Prediction of postoperative complications after major lung resection: a literature review.
2. materials and methods, 2.1. inclusion criteria, 2.2. exclusion criteria, 2.3. search strategy, 2.4. bias assessment, 4. discussion, 4.3. vo 2max, 4.4. pi max and pe max, 5. conclusions, author contributions, institutional review board statement, informed consent statement, data availability statement, conflicts of interest.
Click here to enlarge figure
Study, Year | Country | Design | Sample | Place | Parameters Tested | NOS Score | Results |
---|---|---|---|---|---|---|---|
Almquist et al., 2018 [ ] | USA | Retrospective study | 149 patients undergoing lung resection for lung cancer | Operating room | FEV1 DLCO | 8 stars | FEV1 and DLCO are correlated with length of hospital stay, but not postoperative complications |
Brunelli et al., 2004 [ ] | Italy | Prospective study | 190 patients undergoing lung resection | Operating room | FEV1 DLCO | 8 stars | Estimated and observed losses of FEV1 and DLCO have no significant differences |
Alam N. et al., 2007 [ ] | USA | Retrospective study | 1428 patients undergoing lung resection | Operating room | FEV1 DLCO | 8 stars | The possibility of postoperative lung injury increases, as FEV1 and DLCO drop |
Ferguson M. et al., 2007 [ ] | USA | Retrospective study | 1046 patients undergoing lung resection | Operating room | DLCO | 8 stars | Postoperative predictive DLCO predicts pulmonary morbidity and operative mortality |
Ferguson M. et al., 2012 [ ] | USA | Retrospective study | 854 patients undergoing lung resection | Operating room | DLCO | 8 stars | DLCO is an independent predictor of long-term survival |
Licker M. et al., 2011 [ ] | Switzerland | Observational study | 210 patients undergoing lung resection for lung cancer | Operating room | VO | 7 stars | Cardiopulmonary complications increase as VO decreases |
Bobbio A. et al., 2009 [ ] | Italy | Prospective study | 73 patients undergoing lung resection | Operating room | VO FEV1 | 7 stars | Patients with lower preoperative VO and FEV1 have more postoperative complications |
Refai M. et al., 2013 [ ] | Italy | Prospective Cohort study | 283 patients undergoing lung resection | Operating room | PI PE | 8 stars | Greater PImax reduction after exercise is associated with more complications |
Algar et al., 2002 [ ] | Spain | Retrospective study | 242 patients undergoing pneumonectomy for lung cancer | Operating room | FEV1 | 6 stars | Patients with low ppo-FEV1 are at increased risk for PC after pneumonectomy |
Cundrle Jr et al., 2022 [ ] | Czech Republic | Prospective study | 398 patients scheduled for lung resection surgery | Operating room | FEV1 DLCO | 7 stars | 9% of patients with normal FEV1 and DLCO developed PPC |
Cerfolio et al., 2009 [ ] | USA | Retrospective study | 906 patients undergoing thoracic surgery | Operating room | FEV1 DLCO | 7 stars | Identification of ppoDLCO% and ppoFEV1% as significant independent predictors of respiratory morbidity |
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
Roungeris, L.; Devadze, G.; Talliou, C.; Griva, P. Prediction of Postoperative Complications after Major Lung Resection: A Literature Review. Anesth. Res. 2024 , 1 , 146-156. https://doi.org/10.3390/anesthres1020014
Roungeris L, Devadze G, Talliou C, Griva P. Prediction of Postoperative Complications after Major Lung Resection: A Literature Review. Anesthesia Research . 2024; 1(2):146-156. https://doi.org/10.3390/anesthres1020014
Roungeris, Loizos, Guram Devadze, Christina Talliou, and Panagiota Griva. 2024. "Prediction of Postoperative Complications after Major Lung Resection: A Literature Review" Anesthesia Research 1, no. 2: 146-156. https://doi.org/10.3390/anesthres1020014
Further information, mdpi initiatives, follow mdpi.
Subscribe to receive issue release notifications and newsletters from MDPI journals
An official website of the United States government
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
The PMC website is updating on October 15, 2024. Learn More or Try it out now .
Khalid a alnemer.
1 Department of Internal Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University, Riyadh, SAU
Acute myocardial infarction (AMI) continues to be a predominant cause of global morbidity and mortality, with in-hospital mortality (IHM) serving as a pivotal metric for patient outcomes. This review explores the influence of several clinical variables on IHM in individuals with AMI. Factors such as age, gender, body mass index (BMI), smoking habits, existing comorbidities, prior coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), and biomarkers, including high-sensitivity cardiac troponin T (hs-cTnT) and creatine kinase MB (CK-MB), significantly affect the prognosis of the patient. Advanced age and comorbid conditions such as diabetes and hypertension exacerbate myocardial damage and systemic impacts, thus increasing IHM. Gender and BMI are also critical, and women and patients with obesity face different risks. Smoking increases both the risk of AMI and IHM, underscoring the importance of cessation interventions. ST-elevation myocardial infarction is associated with elevated IHM and requires immediate reperfusion therapy, while non-ST-elevation myocardial infarction requires customized management for risk assessment. Previous CABG and PCI add complexity to AMI treatment and elevate IHM due to pre-existing coronary pathology and the intricacies of the procedures involved. The application of biomarker-centered techniques facilitates the swift identification of individuals at elevated risk, improves therapeutic planning, and reduces IHM for patients with AMI. Understanding and incorporating these clinical determinants are essential to optimize the management of AMI, minimize IHM, and improve patient outcomes. This all-encompassing strategy requires ongoing research, quality improvement efforts, and personalized care approaches.
Acute coronary syndrome (ACS) represents a common clinical manifestation of cardiovascular disease (CVD), which annually results in a large number of hospital admissions and emergency department consultations around the world [ 1 ]. Despite advances in reperfusion strategies and improvements in supportive pharmacological treatments, people with acute myocardial infarction (AMI) continue to experience a significant likelihood of subsequent cardiovascular events and mortality rates (8.9 million deaths worldwide in 2019) that are noteworthy [ 1 - 3 ]. Consequently, many risk determinants and prognostic indices have been established to forecast short- and long-term detrimental consequences [ 4 ].
The prevalence of AMI or ACS in the elderly has decreased significantly due to improvements in both primary and secondary CVD prevention methods. However, a similar decline is not evident among younger demographics, as defined by Ando et al. [ 5 ]. Despite the advances in pharmacological treatment and cardiac catheterization techniques, the rate of in-hospital mortality (IHM) for those with AMI remains an area fraught with clinical complexities. It is imperative to discern the clinical determinants related to IHM within this group. This knowledge is vital for practical risk assessment, prognosis determination, and design of interventions designed to improve patient survival rates; these points were critically analyzed [ 6 ].
As innovative approaches to managing AMI (such as fibrinolytic and invasive therapies) emerge, frameworks to assess mortality risk also advance. In recent times, numerous models have been established to measure mortality risk among patients with myocardial infarction (MI), which includes impairment in diastolic and systolic function, atherosclerotic disease, and coronary artery anomalies [ 7 ]. These models consider immediate (during hospitalization) and extended (across various intervals after discharge from medical facilities) outcomes. Among these are clinical scoring instruments specifically designed for application in hospital settings, offering cardiologists practical tools for day-to-day use in clinical settings [ 8 ].
Primary percutaneous coronary intervention (PCI) is recognized as the superior method of reperfusion treatment for AMI, particularly in cases where patients have ST-segment elevation myocardial infarction (STEMI). However, research focusing on younger demographics needs to be more varied due to their relatively low rates of AMI manifestation [ 5 ]. The European Society of Cardiology (ESC) endorses clinical scales that assess mortality risks among MI sufferers within its most recent directives on MI management. Currently, the GRACE score is valued for its exceptional discriminatory capacity. Thus, it is the fundamental index for evaluating individuals with NSTEMI (non-ST-elevation myocardial infarction) [ 9 ]. Observational studies from the United States and Canada have documented a substantial decrease in IHM rates among patients with AMI who received PCI intervention compared to those who did not [ 10 ]. For clinicians, risk evaluation metrics play an integral role by enhancing clinical judgment processes, informing about appropriate pharmacological treatments, helping to determine the necessary lengths of hospital stays, and helping to craft follow-up care after discharge strategies [ 8 ].
When examining contemporary methodologies to assess mortality risk in patients with AMI, it becomes evident that they predominantly use a consistent array of factors. These include initial clinical challenges, vital statistics observed upon hospital admission, laboratory test results, and presentation of MI as seen on electrocardiograms (ECG), all gauged during the initial patient encounter. By analyzing these variables, healthcare professionals can determine the preliminary mortality risk for those hospitalized with confirmed MI. At the heart of the management of AMI lies a comprehensive grasp and synthesis of various clinical indicators that shape patient outcomes, delineate risk categories, and influence IHM rates.
Our current review of the literature investigates the principal clinical determinants linked to IHM among individuals diagnosed with AMI. The probability of survival after an AMI diagnosis differs markedly between the demographics of the patients due to a multitude of factors, such as gender variance, ethnic background, chronological age, specific types of AMI, pre-existing health conditions, and chosen medical interventions [ 10 ]. Our goal is to integrate existing clinical research findings and authoritative protocols to provide an exhaustive analysis of prognostic indicators of IHM and their implications for evaluating risk and guiding treatment choices. By elucidating these elements, we intend to deepen our understanding of the intricate mechanisms that influence mortality associated with AMI and contribute insights conducive to refining patient care delivery while striving toward decreasing death rates.
Clinical factors associated with IHM in patients with AMI
Effective handling of AMI requires a thorough understanding and synthesis of multiple clinical elements such as age, gender, co-morbidities (like hypertension (HTN) and diabetes), body mass index (BMI), biological markers, etc. These collective elements dictate the patient's prognosis, risk assessment, and treatment results, underscoring the need for a multidisciplinary method and personalized care tactics to improve results and minimize hospital mortality in patients with AMI.
The crucial role of age in AMI-induced IHM cannot be understated, given its extensive influence on the patient's physiological state, the severity of comorbid conditions, and their response to treatment. It is well established that advanced age is a substantial standalone forecaster of negative results in patients with AMI.
With age, the cardiovascular system undergoes physiological transformations such as increased arterial rigidity, abnormal myocardial contractility and relaxation, and impaired coronary circulation [ 11 ]. Approximately 30-40% of all hospitalized patients with ACS are adults 75 years and older, and a significant proportion of ACS-related deaths are observed in this demographic within the United States [ 12 , 13 ]. Age is a significant risk factor for diffuse coronary disease and a worsening prognosis in hospitalized patients with unstable angina (UA) or NSTEMI [ 14 ]. The TIMI III registry revealed that patients 75 years and older with UA/NSTEMI exhibited more extensive and severe coronary disease, experiencing poorer outcomes both during hospitalization and within the first six weeks after discharge compared to those under 75 years of age [ 14 ].
Elderly individuals frequently exhibit an increased prevalence of concurrent medical conditions, including HTN, diabetes mellitus (DM), chronic renal disease, and peripheral vascular disease, which are recognized risk factors for cardiovascular events and IHM in patients with AMI [ 15 ]. In the same article, the coexistence of multiple comorbidities was reported to complicate the clinical management of AMI and increase the risk of IHM. Death rates have been documented to be higher in 55 and older patients compared to those under 55 years of age (OR: 4.07; 95% CI: 2.16-7.64) [ 15 ].
Elderly individuals may show unusual or vague signs of AMI, such as exhaustion, breathlessness, or disorientation, which could delay recognition and diagnosis of the critical incident [ 16 ]. The average duration from the appearance of symptoms to the initial medical interaction was recorded at 12.7 hours, with a range of 10 minutes to 96 hours. Increased the incidence of IHM [ 7 ]. Additionally, Khan et al. concluded that the non-standard manifestations of MI are extensive; patients may suffer from chest pain lacking the typical characteristics of angina pectoris or may not experience chest pain at all. Most of the patients were elderly and generally had pain and discomfort in the abdominal, cranial, and cervical areas [ 7 ]. Multiple research studies have established a strong link between advanced age and elevated IHM rates among patients with AMI with diabetes (OR: 2.33; 95%CI: 1.42-3.81; p= 0.001 [ 15 ], with heart failure of AMI at 25.9% [ 17 ]. Elderly subjects (about 6.3% above age 80 yrs) show higher short-term and long-term mortality rates after AMI compared to their younger counterparts, where IHM was associated with hypoxia at admission (OR: 1.70; 05%CI: 1.30-2.22) [ 18 ]. There was a notable association between age-adolescence and increased mortality rates among patients with AMI (P = 0.001) [ 15 ]. Older adults often suffer from chronic low-grade inflammation, which is associated with frailty and CVD [ 13 ]. A person who is frail is characterized by a physiological decline across multiple organ systems which increases vulnerability to stressors, increasing the likelihood of functional decline, hospitalization, and death [ 19 ]. In patients with frailty, less aggressive approaches may yield better outcomes due to increased risk for adverse outcomes. Clinical practitioners are advised to manage competing noncardiac risks in frail patients with MI by paying more attention [ 19 ].
In the realm of AMI and IHM, gender is a significant clinical variable that influences patient presentation, treatment approaches, and eventual outcomes. Historically, men have been perceived to be more susceptible to AMI than women, especially in their younger years [ 20 ]. On the contrary, women tend to experience AMI later in life (57± 7 years), often accompanied by nontraditional symptoms, which could result in missed diagnoses and treatment delays [ 20 , 21 ]. A 2022 study by Rohani et al. revealed that 18.8% (n = 105) passed away before discharge of all MI patients admitted to the hospital [ 15 ]. About 28.4% of these fatalities were women, while men accounted for 13.6%. When analyzing these groups, it was found that 88.7% (n = 93) of those who did not survive belonged to the age group 55 years or older.
The risk factors for AMI are differentially distributed between genders, leading to distinct patterns in its manifestation and prognosis. Women are more likely to suffer from comorbid conditions such as HTN, diabetes, and obesity. In contrast, men show a higher propensity toward habits such as smoking and excessive alcohol use [ 22 , 23 ]. It is hypothesized that estrogen confers cardio-protection, resulting in a lower incidence of AMI in premenopausal women compared to men of the same age [ 24 ]. However, this cardioprotective effect decreases after menopause, increasing the risk of AMI in older women. Asgari et al. found in their investigation that the majority (66.3%) of MI patients were male [ 25 ]. Rohini et al. observed that most of the hospitalized women (85%) were 55 years or older, while only 62% of the men belonged to this age group [ 15 ]. The literature reveals gender-based discrepancies in AMI management, with women receiving recommended treatments such as aspirin, beta-blockers, and reperfusion therapy less frequently. These disparities could potentially lead to poorer outcomes and higher mortality rates among women [ 23 ]. Numerous studies indicate elevated mortality rates in the hospital and 30 days after MI in women compared to men [ 26 ]. This trend is particularly evident among younger women (under 55), with the gender disparity decreasing with age [ 26 ]. For example, research by Nazzal and Alonso revealed a high IHM rate in women under 45 years of age (OR: 2.3; 95%CI: 1.5-3.3) [ 27 ]. The increase in early mortality in females is believed to be due to differences in the presentation of symptoms [ 28 , 29 ].
Elgendy et al. identified that, compared to their male counterparts, women who experienced AMI accompanied by cardiogenic shock received guideline-based treatment less frequently within the initial 24 hours and at the time of discharge [ 30 ]. This gender-based discrepancy has previously been observed in patients with AMI, regardless of the presence of cardiogenic shock [ 31 ]. Previous studies have confirmed that women are less likely to undergo cardiac catheterization and receive mechanical circulatory support devices [ 32 ]. On a positive note, the research did not reveal differences in the frequency of primary PCI among STEMI patients [ 32 ]. However, women were less likely to achieve a door-to-device time of less than 90 minutes [ 30 ]. The root of this delay remains unclear, whether it is attributable to patient-specific or system-wide delays in the recognition of STEMI (for example, due to gender-related variances in the presentation of symptoms or the ability of healthcare professionals to identify and appreciate symptoms) or whether it stems from post-STEMI recognition care is undetermined in the analysis by Elgendy et al. [ 28 ].
Smoking is acknowledged as a contributing determinant of IHM in AMI scenarios, essentially accelerating the onset of STEMI in subjects supposedly healthier [ 33 ]. Although smoking plays a crucial role in the onset of atherosclerosis, numerous studies have indicated that smokers who receive fibrinolytic treatment for AMI exhibit better outcomes compared to non-smokers, as it causes thrombosis, arterial inflammation, and dilatation and dysfunction [ 34 ]. This phenomenon is called the "smoker paradox." For example, GUSTO I, the most extensive trial evaluating the impact of smoking on clinical outcomes, included 11,975 non-smokers, 11,117 former smokers, and 17,507 current smokers. Non-smokers showed significantly higher IHM (9.9% versus 3.7%) and 30-day mortality rates (10.3% versus 4.0%) [ 35 ]. The superior results observed in smokers after fibrinolysis can be attributable to several factors: first, smokers often have elevated levels of hematocrit and baseline fibrinogen, indicating a hypercoagulable state. These more active thrombogenic processes can lead to a more significant thrombus burden, which is more amenable to fibrinolytic therapy, resulting in higher patency rates and a higher probability of achieving TIMI-3 flow in the infarct-related artery after fibrinolysis [ 36 ]. Second, smokers exhibit a more favorable risk profile compared to non-smokers; they are generally younger (average age is 11 years younger in GUSTO I) and show a lower prevalence of diabetes, HTN, previous MI, and severe coronary artery disease [ 37 ].
A study by Song et al. found a decrease in IHM between current smokers and nonsmokers (OR: 0.78, 95% CI: 0.69 to 0.88, p=0.001) [ 38 ]. However, the same study did not observe significant differences in IHM between former smokers and non-smokers (OR: 0.89, 95% CI: 0.77 to 1.04, p=0.1443). Another investigation indicated that smoking was associated with reduced all-cause IHM, with only 6.5% of smokers dying during hospitalization compared to 13.2% of non-smokers (OR: 0.46; 95% CI: 0.34-0.63) [ 39 ].
The risk of AMI is directly related to the duration and severity of smoking habits, with even indirect exposure to tobacco smoke increasing cardiovascular risk [ 40 , 41 ]. A study by Venkatason et al. found a positive link between smoking and improved outcomes in patients with STEMI and NSTEMI [ 42 ]. In the NSTEMI cohort, smokers exhibited a higher incidence of coronary revascularization in the hospital (21.6% for smokers versus 16.7% for non-smokers, P < 0.001). On the contrary, in the STEMI cohort, the rates were comparable between smokers and non-smokers.
A meta-analysis of PCI trials found that smoking is associated with a higher risk of mortality from all causes and heart failure [ 43 , 44 ]. Furthermore, Gao et al. found an increased risk of recurrent MI associated with smoking [ 45 ]. In conclusion, smoking plays a vital role in AMI, affecting its pathogenesis, presentation, treatment, and patient outcomes. Recognizing the harmful impact of tobacco on cardiovascular health emphasizes the need for interventions to stop smoking to reduce morbidity and mortality from CVD and increase its outcome.
Body Mass Index
Obesity, characterized by an elevated BMI, is correlated with an increased probability of cardiovascular diseases such as HTN, dyslipidemia, and DM [ 46 ]. Specific research has identified a counterintuitive U-shaped correlation between BMI and long-term cardiovascular health outcomes. This occurrence, known as the "obesity paradox," indicates that individuals with higher BMI could exhibit similar or even reduced mortality rates compared to those with normal BMI. At the same time, those with very low BMI experience poorer outcomes [ 47 ]. The obesity paradox likely results from the intricate interplay of various potential mechanisms, including energy reserves, nutritional status, earlier detection of cardiovascular symptoms, faster medical response, and chronic oxidative stress and inflammation [ 47 ]. Following are few examples that discuss the importance of BMI as a clinical factor in AMI.
The research carried out by Elbaz-Greener et al. found that hospitalizations for NSTEMI and STEMI were 75.6% and 24.4%, respectively [ 48 ]. The same study identified a BMI below 19 kg/m 2 as an independent predictor of poorer outcomes and IHM through a multivariate analysis (odds ratio (OR): 1.47, 95% confidence interval (CI): 1.29-1.67).
Angerås et al. observed a peak in survival rates among overweight or moderately obese patients (BMI <35), while those who were underweight or had average weight exhibited the highest mortality risk during follow-up periods [ 49 ].
In contrast, some studies contradicted the obesity paradox, showing increased mortality rates in patients with a BMI greater than 40 kg/m 2 [ 50 , 51 ].
Significantly, the underweight group was consistently associated with a significantly elevated risk of IHM in all cardiovascular diseases compared to the standard BMI group (OR: 1.52, 95% CI: 1.45-1.60) [ 52 ].
Some studies reported a J-shaped relationship between BMI and mortality in patients hospitalized for AMI in recent years. These results confirm that the "obesity paradox" remains relevant in the contemporary management of AMI [ 48 , 53 ].
The TRACE study indicates that among patients experiencing AMI, overall obesity is inversely correlated with mortality rates. Specifically, patients with an underweight AMI exhibited a higher mortality risk (OR: 1.73; 95% CI 1.23-2.44) [ 54 ]. On the contrary, within the same study, overweight women demonstrated a reduced mortality risk (OR: 0.78; 95% CI: 0.68-0.90).
The CRUSADE initiative similarly found that only underweight patients faced an elevated mortality risk (OR: 1.2; 95% CI: 1.0-1.4) [ 55 ].
Ellis et al. observed that patients with a BMI of less than 25 kg/m 2 or more than 35 kg/m 2 had higher mortality rates after PCI [ 56 ].
Powell et al. also identified this bimodal distribution, noting increased mortality risks at both extremes of BMI [ 57 ]. Both studies reported a consistent reduction in adverse outcomes for BMI values below 40 kg/m 2 .
Furthermore, the protective nature of obesity has been proposed to be attributable to larger vessel sizes in general [ 58 ].
Co-morbidities (Diabetes and HTN)
DM and HTN are critical clinical determinants in the realm of AMI and IHM [ 59 , 60 ]. Over the last four decades, significant advances in outcomes have been documented for the general population with AMI, regardless of the status of the DM. However, consistent observation has shown a two-fold increase in IHM rates among DM patients [ 60 ]. In the general population, the incidence of HTN increases progressively with increasing age in both genders; however, it is consistently higher in all age groups in black individuals, posing a more substantial risk factor for coronary artery disease compared to whites. Approximately 54% of Americans aged 65 to 74 years have HTN, whereas the prevalence among black individuals is 72% [ 61 ].
The frequency of mortality in hospital settings was markedly higher among hypertensive patients, registering at 5.9% compared to 4.0% (P <0.001) [ 62 ]. Research indicated that people with HTN and STEMI are more prone to type 2 diabetes and exhibit elevated blood glucose levels upon admission if they do not have a prior diagnosis of diabetes, which adversely impacts their prognosis [ 63 ]. A detailed examination of the Acute Myocardial Infarction Registry (KAMIR), which included data from 8568 Korean patients with STEMI, corroborated that type 2 diabetes is prevalent among patients with hypertensive STEMI. These patients demonstrated poorer clinical and angiographic results, a higher probability of heart failure, and a higher risk of major adverse cardiovascular events (MACE) during long-term follow-up [ 64 ]. Sheifer et al. investigated 102,399 patients with AMI and found that diabetes independently predicted delays in treatment initiation (OR: 1.11, 95% CI: 1.07-1.14) [ 65 ]. Numerous investigations have indicated that patients with AMI who also have diabetes frequently exhibit non-classical symptoms, such as the absence of persistent chest pain, sweating, and referred pain. A history of diabetes has been identified as an independent predictor of such atypical presentations. These results are consistent with previous studies [ 66 , 67 ].
Before coronary artery bypass graft (CABG) and before percutaneous coronary intervention (PCI)
CABG surgery effectively alleviates symptoms and improves patient outcomes. However, patients who undergo CABG typically exhibit advanced stages of coronary atherosclerosis, predisposing them to an increased risk of symptom recurrence and adverse events [ 68 , 69 ]. In contrast, PCI is a non-surgical method aimed at improving coronary blood flow at the site of obstruction through techniques such as balloon inflation, stent deployment, and/or atherectomy performed via a coronary catheter [ 70 ]. The anatomical complexity and blood supply of the coronary artery in patients with a history of CABG differ significantly from those without previous bypass surgery. This complexity complicates the identification of the culprit vessels during emergency angiography, and bypass grafts often complicate the scenario [ 71 ]. In a retrospective study by Liu et al., primary PCI procedures in 78 patients with AMI and previous CABG surgery showed a lower success rate and higher IHM compared to patients without previous bypass surgery [ 71 ]. The mortality rate within the hospital was found to be 4.6 times higher compared to the study counterparts during the equivalent period of time.
In another observational analysis by Blachutzik et al., findings indicated that of 121 patients with prior CABG had 13% IHM, adverse outcomes were related to advanced age and congestive heart failure [ 72 ]. Another investigation, the CAMI registry study that spans 2013-2014, found that 8% of Chinese patients admitted for AMI, including STEMI and NSTEMI with previous CABG and PCI, had a history of previous MI [ 73 ]. A study by Xie et al. demonstrated that CABG produced better results compared to PCI IHM (OR= 1.41, 95% CI 1.22-1.63, p< 0.001) [ 74 ]. The same research reported that the cumulative meta-analysis of all-cause mortality indicated significant differences between CABG and PCI at three years of follow-up, with the disparity becoming notable at five years of cardiac-specific mortality.
Cardiac troponin and creatine kinase-MB as biomarkers
High-sensitivity cardiac troponin T (hs-cTnT) and creatine kinase MB (CK-MB) are widely recognized biomarkers for the clinical diagnosis of AMI [ 75 ]. Measuring cardiac troponin T (cTn-T) in blood is fundamental for identifying MI. As cTnI and cTnT are present exclusively in cardiomyocytes and possess a distinctive cardiac-specific amino acid sequence, they have become the primary biomarkers for the detection of MI or other myocardial injuries [ 76 ]. The guideline-recommended approach to diagnosing MI involves measuring cardiac troponin I (cTnI) or cTnT in the blood [ 77 ]. The leading cause of MI is inadequate oxygen supply and acute ischemia of cardiac tissue [ 77 ]. However, these biomarkers have some limitations, which include sampling over time, poorly predicted long-term outcomes, and unstable angina [ 78 ].
The onset of acute ischemia initiates cardiomyocyte necrosis, which causes the breakdown of cell membranes and organelles, leading to the subsequent release of cellular proteins into the bloodstream. This process results in a significant elevation in cTn levels in the blood, typically peaks within 10-20 hours in patients who undergo reperfusion of blocked coronary arteries or 24-50 hours in those without reperfusion after the onset of acute ischemia [ 79 , 80 ]. Elevated troponin levels can persist for up to 10-14 days after MI, much longer than other markers of MI, such as creatine kinase-MB or myoglobin. It is hypothesized that this extended release of cTnI and cTnT from the tissue is due to the binding of the troponin complex to other elements of thin filaments within cardiomyocytes [ 79 , 80 ].
Numerous investigations have shown that these markers can predict immediate and long-term mortality in AMI and are related to the severity of coronary lesions and the size of the infarct [ 81 - 83 ]. As the estimated glomerular filtration rate (eGFR) decreases, the probability of cardiovascular death increases progressively, with approximately half of patients with advanced chronic kidney disease (CKD). In a study involving 5022 patients, 70.5% were diagnosed with STEMI, while 29.5% had NSTEMI [ 83 ]. The same research indicated that as eGFR decreased, high-sensitivity cardiac troponin T (hs-cTnT) and IHM increased. At the same time, creatine kinase-MB (CK-MB) did not show a proportional increase, leading to an elevated cTnT/CK-MB ratio. Chronic kidney disease (CKD), a critical prognostic factor in AMI, also affects troponin T levels [ 84 ]. A recent meta-analysis highlighted the high sensitivity of hs-cTnT in predicting mortality among patients with CKD, noting that each 10 ng/L increase in hs-cTnT is associated with a 14% increase in the risk of all-cause mortality [ 85 ]. The ratio of hs-cTnT to CK-MB also shows promise as a tool for risk stratification in people with AMI and CKD [ 83 ]. In an additional study by Sivarajah et al. involving 420 patients, the primary outcome of IHM was significantly higher in the group with elevated cTn levels (14.6% vs. 6.3%; p = 0.008) [ 86 ].
CK-MB demonstrates a clinical sensitivity of 90% for the diagnosis of AMI, but its relatively low specificity counterbalances this. It is detectable within 12 hours after the onset of AMI symptoms, reaches peak serum concentrations at 24 to 36 hours, and normalizes in 48 to 72 hours. Due to these release kinetics, total CK measurement is inadequate for the early diagnosis of AMI in six hours [ 87 ]. To improve the cardiac-specific diagnosis of AMI, measuring both total CK and CK-MB is suggested, the latter being the cardiac-specific isoenzyme of CK. A CK-MB to CK ratio greater than 6% indicates myocardial injury, while a ratio less than 6% suggests skeletal muscle damage or other non-cardiac causes [ 87 ]. Elevated levels of CK-MB in STEMI patients undergoing primary angioplasty are associated with higher mortality rates; however, the relationship between these values and short-term outcomes remains undetermined [ 88 ].
Research by Rakowski et al. indicated that the level of CK-MB measured 12 hours after PCI emerged as a more accurate predictor of infarct size at six months compared to levels measured 6, 18, 24, and 48 hours after PCI. This measurement was also more reliable than the CK-MB area under the curve and the peak CK-MB values [ 89 ]. Furthermore, CK-MB levels significantly correlate with IHM rates in patients with STEMI who underwent PCI [ 90 ]. According to research by Dohi et al., analysis of peak CK-MB levels may be an effective method to estimate the infarct size and predict left ventricular dysfunction. In particular, a peak level of CK-MB that exceeds 300 U/L can be expected to result in around 80% of patients having a large STEMI (infarct size ≥ 17%) following early reperfusion therapy [ 91 ].
Acute management of MI is a complex task that requires understanding and amalgamating numerous clinical factors to improve patient outcomes. In individuals with AMI, clinical variables such as age, sex, smoking status, BMI, comorbid conditions, history of CABG, and PCI, along with biomarkers, affect presentation, prognosis, and therapeutic approaches. Due to physiological changes associated with aging, gender, BMI, smoking, and an increased burden of comorbidities, these clinical factors play an important role in the outcomes of AMI. Patients with HTN, DM, and CKD find it more challenging to manage AMI and have a worse prognosis because they increase myocardial damage. Customized management strategies and comprehensive risk assessments are essential for patients with AMI to optimize outcomes and lower mortality rates.
Patients with DM and HTN are at risk of AMI because they have comorbidity conditions and require personalized treatment approaches. The history of previous CABG or PCI plays a crucial clinical role in AMI, where overall outcomes are affected. A personalized treatment plan and specialized medical attention are necessary to improve results and minimize hospital mortality. Managing AMI in individuals with a history of CABG or PCI requires close collaboration between cardiologists, cardiac surgeons, and multidisciplinary teams. Management of IM relies on biomarkers to diagnose, prognostic, and assess risk. The IHM of patients with AMI is reduced by using biomarker-based methods to quickly detect high-risk individuals. AMI risk prediction and personalized care can be advanced through ongoing research and enhancement of these clinical factors.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Concept and design: Khalid A. Alnemer
Acquisition, analysis, or interpretation of data: Khalid A. Alnemer
Drafting of the manuscript: Khalid A. Alnemer
Critical review of the manuscript for important intellectual content: Khalid A. Alnemer
Background Rare diseases (RD) like akute porphyrias (APs) present a particular challenge for emergency physicians (EP), as their acute symptoms are usually nonspecific and resemble common clinical presentations. This is compounded by low awareness and limited training of EP regarding RD, often leading to patients with RD being discharged without an accurate diagnosis. Consequently, despite the availability and necessity of targeted diagnostic and treatment options, RD patients may experience further complications and fatal outcomes. This study aimed to characterise patients with RD, such as APs, in the ED and to raise awareness of the problem of unrecognised rare but treatable diseases in the ED.
Methods The BEAWARE study conducted from July 2023 to June 2024 surveyed patients with RD throughout the German-speaking area, focusing on acute symptoms and presentations in the ED. A select group of RD, including AHP, was chosen to meet the following criteria: (a) causing acute symptoms, (b) diagnosable in the ED for adolescents or adults and (c) availability of therapeutic options. In addition, Embase and MEDLINE were searched up to November 2023 in a systematized literature review of articles on the clinical characteristics of patients with AHP in the ED.
Results A total of 147 RD patients (15 with APs) participated in the survey. Except for one patient, all AP patients (93.3%) reported that they did present to the ED prior to diagnosis. 8/14 of AP patients presented to the ED 1–2 times, 4/15 3–5 times, 1/15 11–20 times and 1/15 more than 20 times with symptoms of their later diagnosed AP.
Of 327 identified articles, 3 could be included that described the clinical presentation of 59 AP patients in the ED. The most common symptoms were abdominal pain (53/59) and neurological symptoms (confusion, paresis, numbness of the extremities, and seizures). The main reported trigger factors included menstrual cycle (28/36) and medication (8/49). Imaging typically yielded unremarkable results. Vital signs were within normal ranges for most patients and hyponatremia was observed in 32/46 patients. The patients‘ outcomes ranged from hospital release after two days to respiratory paralysis (in 3/59 patients) followed by three months of recovery and death in one patient due to a delay in diagnosis for a month.
Discussion and Conclusion Patients with APs frequently present to the ED prior to diagnosis and remain often undiagnosed for several visits. The sometimes serious and even fatal consequences emphasize the need for immediate diagnosis and treatment of APs in the ED.
Awareness and knowledge of rare diseases such as APs should be increased in the emergency department. So far, little is known in the literature about the presentation of AP patients in the emergency department. Perhaps AI-supported algorithms can support rapid diagnosis in the future.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .
https://doi.org/10.1136/bmjgast-2024-ICPP.80
Request permissions.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Background Concerns have recently been raised about risks to the fetus resulting from paternal exposure to antiseizure medications (ASMs). To address these concerns, we conducted a systematic review of the literature to assess neurodevelopmental and anatomical outcomes in offspring born to fathers taking ASMs at the time of conception.
Methods Electronic searches of MEDLINE, PsycINFO, and Embase were conducted to identify human studies published in English that reported on outcomes, comprising neurodevelopmental disorders, major congenital malformations, small-for-gestational age or low birth weight, in offspring of fathers taking ASMs at conception. Quality analysis of included studies was undertaken using the Newcastle-Ottawa Scale. A narrative synthesis was used to report study findings.
Results Of 923 studies identified by the search and screened by title and abstract, 26 underwent full-text review and 10 met eligibility criteria. There was limited evidence available, but there appeared to be no clear evidence for an adverse impact of paternal ASM use on offspring outcomes. Few isolated adverse findings were not replicated by other investigations. Several methodological limitations prevented meta-analysis, including failure by most studies to report outcomes separately for each individual ASM, heterogeneity in measurement and outcome reporting, and small numbers of monotherapy exposures.
Conclusions Although there were limited data available, this systematic review provides reassuring evidence that paternal exposure to ASMs at conception is unlikely to pose any major risk of adverse outcomes for the offspring. Further research is needed to examine the relationship between preconception ASM use in males and offspring outcomes at birth and postnatally.
Data are available upon reasonable request.
https://doi.org/10.1136/jnnp-2024-334077
Request permissions.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
While maternal use of some antiseizure medications carries an elevated risk of adverse outcomes for the developing fetus, it is unclear whether paternal exposure to these drugs also carries risks for the offspring.
Our systematic review shows that evidence for any risk to the offspring resulting from paternal exposure to antiseizure medications is scarce and inconsistent, with most studies showing no increased risk compared with unexposed controls. Therefore, the available evidence does not justify major concerns.
The results of our study inform the counselling of males with epilepsy and highlight the need for more research in this area, focusing in particular on risks associated with individual medications.
The teratogenic effects of antiseizure medications (ASMs) taken by mothers are well-documented. 1 In contrast, the outcomes of offspring of fathers taking ASMs have received substantially less attention. In recent years, however, preclinical studies have clearly demonstrated that epigenetic changes in the paternal germline induced by drugs or toxins can lead to anatomical teratogenicity and adverse neurodevelopmental effects in the offspring. 2 3 These findings raised important concerns and highlighted the need to determine their potential applicability to the clinical setting. 4
Adverse effects of ASMs on male fertility have been frequently documented. 5 Of note, many ASMs, including phenytoin, carbamazepine, benzodiazepines, valproate, gabapentin, topiramate, zonisamide, levetiracetam, pregabalin, and cannabidiol have been reported to cause testicular toxicity or to affect sperm quality in experimental animals. 6–14 Transgenerational effects have also been reported, including anatomical teratogenicity in the offspring of male mice treated with pregabalin, 13 behavioural abnormalities and impaired reproductive function across multiple generations after paternal exposure to cannabidiol in zebrafish, 15 behavioural abnormalities in the offspring of male mice treated with valproate, 16 17 and transgenerational transmission of autism-like phenotypes by the offspring of mice exposed to valproate during pregnancy. 18 Clinically, alterations in sperm count, morphology or motility have been associated with valproate, 19–21 carbamazepine, 20 oxcarbazepine, 20 and levetiracetam, 22 even though for some of these ASMs findings are inconsistent. 23 Because of its common association with anatomical and behavioural teratogenicity after maternal exposure, valproate has undergone particular scrutiny with respect to potential male reproductive toxicity. A 2023 report by the Medicines and Healthcare products Regulatory Agency (MHRA) 21 in the UK, highlighted that many studies support its testicular toxicity in preclinical models and its effects on human sperm quality, as well as the risk of impaired fertility in men exposed to the drug. A potential transgenerational transmission of anatomical and neurodevelopmental disorders resulting from prenatal exposure to valproate was suggested by a French survey, 24 but the results of this report cannot be meaningfully interpreted due to a high likelihood of reporting and ascertainment bias. Greater concerns, however, were raised by a recent register-based study commissioned by the European Medicines Agency (EMA), yet to be published in full following peer review, which apparently found a 50% increased risk of neurodevelopmental disorders in children born to men taking valproate compared with those born to men on lamotrigine or levetiracetam. 25 26 Notably, the EMA acknowledged that the study was hampered by methodological limitations and could not establish whether the adverse offspring outcomes were actually attributable to paternal valproate exposure. 25
Motivated by the aforementioned experimental data and the study commissioned by the EMA, we performed a systematic review of the literature in humans to examine the neurodevelopmental and anatomical outcomes in offspring of fathers taking ASMs around the time of conception.
The protocol for this review was developed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. The review protocol was registered on PROSPERO on 20 November 2023 (registration number CRD42023481600).
This systematic review included articles that reported on the outcomes of children paternally exposed to ASMs, either as monotherapy or polytherapy, with no restrictions placed on the indication of usage. Exposure was defined as paternal use of ASMs at the time of, or in the months before, conception. Eligible study designs included the following: observational cohort studies, population-based datasets, register-based studies, and case-control studies. No restrictions were placed on the time of publication, but eligible studies were required to report original data and be in English language. We excluded animal studies, studies that only reported on child outcomes following maternal ASM exposure, duplicate publications reporting the same data, review articles, commentaries, letters to the Editor, studies where the number of exposed offspring was <10, and studies where the full text was not available.
The electronic search terms were developed in consultation with a tertiary librarian ( online supplemental file 1 ). Electronic searches of Medline, PsycINFO, Embase were conducted in November 2023, with additional hand searching of Google Scholar (related articles) and reference lists of included studies to identify articles not captured in primary searches. Electronic searches, utilising the same strategy and screening procedure, were updated in June 2024 to identify any additional eligible studies published since the original searches, resulting in the identification of one new eligible study. Two reviewers (EH and EP) independently screened titles and abstracts for eligibility, reviewed full-text articles for inclusion, extracted data and rated the quality of included studies in Covidence, with discrepancies resolved by a third reviewer (PP).
Data synthesis and reporting.
Extracted data pertaining to study information and population characteristics included: study design, country, method of participant recruitment (eg, prospective pregnancy register, national population dataset), demographic and clinical characteristics of the father (age, exposure to other teratogens, education level and health status (if known)), number of exposed offspring and their demographic information (age, sex), and recruitment of comparison group (if applicable). The primary outcome was risk of adverse outcomes, including neurodevelopmental disorders (eg, autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), intellectual disability (ID), developmental delay, or other developmental problems), major congenital malformations (MCMs), small-for-gestational age (SGA), and low birth weight in offspring of fathers treated with ASMs. Extracted outcomes were expressed as odds, hazard, or risk ratios, with associated 95% confidence interval (95% CI).
The quality analysis of included studies was assessed independently by two reviewers (EH and EP) using the Newcastle Ottawa Scale (NOS), a risk of bias tool recommended for evaluating non-randomised studies. 27 Studies received a maximum of 8 points across three domains: selection of study groups (3 points); comparability of study groups (2 points); and ascertainment of exposure and outcomes (3 points).
Due to the small number of eligible studies and heterogeneity of outcomes data, a meta-analysis could not be performed. Extracted data was synthesised into a narrative review reporting the risk of adverse outcomes. Findings were provided separately by ASM type, where applicable, with the strength of evidence commented on within each section.
Access to the study data will be considered on reasonable request to the corresponding author.
A total of 1298 titles were identified through electronic and manual searches. After removal of duplicates, 923 articles underwent title and abstract screening ( figure 1 ). Of these, 26 underwent full-text review for assessment of eligibility, yielding 10 studies which were included in the final review. Of the included studies, there were six population-based cohort studies, three prospective cohort studies, and one cross-sectional study. Further details on the studies included in the final review are presented in table 1 .
PRISMA flowchart of study selection. ASM, antiseizure medication.
Study characteristics of the included articles
The quality of the included studies was variable ( table 2 ). One study did not have an unexposed cohort to which outcome data could be compared, 28 which resulted in lower quality assessment ratings. In one study, it was unclear how paternal ASM exposure status was ascertained; the cohort was labelled as ‘offspring of men with epilepsy’, and it was assumed via the outcome data that all men were ASM-treated but the study methodology lacked sufficient description. 29 Only one study controlled for ASM dose (>750 mg/d vs ≤750 mg/d valproate), 30 and only three studies reported findings separately for each ASM as opposed to a class, 31 32 although some studies controlled for relevant confounding variables in outcome analyses, including paternal or maternal age, past history of psychiatric disorders, and exposure to other teratogens. The quality analysis ratings for the outcome assessment category ratings were the most variable; population-based studies recorded outcomes through secure record linkage to databases which are subject to variable diagnostic accuracy and lack information on important variables, whereas other studies relied on self-reporting, which is subject to recall bias, or did not adequately describe how outcome data were collected.
Quality analysis of studies included in the review
Neurodevelopmental outcomes of offspring paternally exposed to ASMs are summarised in table 3 and online supplemental table 1.
Neurodevelopmental outcomes of offspring paternally exposed to ASMs at time of conception
A retrospective nationwide population-based study from Denmark found no significant increase in overall risk of neurodevelopmental disorders (composite outcome, comprising ID, ASD, ADHD, and disorders of psychological development) in the offspring of fathers exposed to valproate (n=1336) compared with offspring of valproate-unexposed fathers (n=1,234,017), adjusting for potential confounders. 30 Similar results were obtained when undertaking a series of additional analyses, such as restricting the analysis to offspring of fathers exposed to high-dose valproate (>750 mg/d) or lower doses of valproate, or when excluding disorders of psychological development ( table 3 ).
One prospective cohort study found a significantly increased risk of autistic traits among 18-month-old offspring of fathers who took ASMs within 6 months of conception (n=147) compared with unexposed controls (n=60 583). 33 However, there was no significant increase in proportion of offspring meeting the cut-off for ASD on another screening instrument at the same time point, and the increased risk of autistic traits was no longer identified at age 36 months in a smaller cohort (n=110). Three population-based studies found no significantly increased risk of ASD diagnosis compared with unexposed controls among offspring exposed to any ASM (n=2087), 31 benzodiazepines (n=64 570), 34 valproate (any exposure n=1336, >750 mg/d n=715, ≤750 mg/d=721, monotherapy n=1017), 30 valproate monotherapy (n=458), 31 carbamazepine monotherapy (n=582), 31 or other ASM monotherapies (n=605). 31
There was no increased risk of ADHD traits among 36-month-old offspring paternally exposed to ASMs (n=110) compared with unexposed controls (n=43 571) in a prospective cohort study. 33 Population-based studies found no increased risk of ADHD diagnosis compared with unexposed controls following paternal exposures to any ASM (n=2087), 31 benzodiazepines (n=64 570), 34 valproate monotherapy (n=458), 31 carbamazepine monotherapy (n=582), 31 or other ASM monotherapies (n=605). 31
Intelligence quotient (IQ) at age 4 years was within normal limits among offspring of fathers with epilepsy treated with ASMs at the time of conception (n=396). 29 One population-based study found no increased risk of ID diagnosis compared with unexposed controls for offspring paternally exposed to any ASM (n=2087), valproate monotherapy (n=458), carbamazepine monotherapy (n=582), or other ASM monotherapies (n=605). 31
In a cohort of ASM-exposed offspring that also had elevated autistic traits, these children (n=147) were significantly more likely to score outside the normal range on a measure of personal-social skills compared with unexposed controls born to fathers without epilepsy (n=60 583). 33 Gross motor skills, fine motor skills, communication skills, aggressive symptoms, and difficult temperament were all within normal limits for ASM-exposed offspring at 18 months (n=177) and at 36 months (n=110) compared with unexposed controls (n=60 583) 33 35 ( online supplemental table 1 ).
A full description of findings on the risk of MCMs following paternal ASM exposure is reported in table 4 . Among cross-sectional and prospective cohort studies, there was no elevation in the rate of MCMs among offspring paternally exposed to ASMs (n=396) compared with maternal ASM exposures (n=305), or unexposed offspring (n=49 590) 29 ; no MCMs reported among 22 ASM-exposed offspring 28 ; and no significant increase in MCMs among 241 ASM-exposed offspring compared with unexposed controls (n=106 899). 33 In population-based studies, no increased risk of MCMs was found among offspring of fathers exposed to diazepam (n=1354), 36 benzodiazepine-derived anxiolytics (n=3047) or benzodiazepines as hypnotics/sedatives (n=736), 37 any ASM (n=2087, 31 valproate (monotherapy n=458 31 any exposure n=805 32 , any exposure n=1,336 30 , >750 mg/d n=715 30 , ≤750 mg/d n=621) 30 , carbamazepine (monotherapy n=582 31 , any exposure n=687) 32 , or other ASM monotherapies (n=605) 31 compared with unexposed offspring.
Anatomical outcomes in offspring paternally exposed to ASMs at time of conception
One study found a mildly increased risk of congenital anomalies in offspring exposed to any ASM, as well as lamotrigine (n=612) and oxcarbazepine (n=587). 32 However, the study did not distinguish between minor and major anomalies, and did not report the type of ASM treatment (monotherapy or polytherapy) or doses used. Moreover, based on additional comparisons, the authors concluded the difference may be attributable to the underlying indication rather than ASM exposure.
Data on SGA or birth weight in relationship to paternal ASM exposure are provided in table 4 . There was no significant increase in the number of infants born SGA in one prospective cohort study of ASM-exposed offspring (n=241) when compared with unexposed offspring (n=106 899). 33 One population-based study of diazepam-exposed infants (n=1354) found an increase in the rates of SGA compared with unexposed offspring (n=3 36 893); however, the authors noted that the finding may be confounded by maternal age and smoking status. 36
One cross-sectional study reported normal birth weight for infants paternally exposed to ASMs (n=22), 28 and a prospective cohort study found no increase in the number of ASM-exposed infants (n=241) with low birth weight compared with unexposed controls (n=106 899). 33
One prospective cohort study found no increase in the rates of low APGAR scores or pre-term births among infants exposed to ASMs (n=241) compared with unexposed offspring (n=1 06 899) 33 ( online supplemental table 1 ). A population-based study of offspring paternally exposed to diazepam (n=1354) found more than a two-fold increased risk of perinatal mortality compared with unexposed offspring (n=3 36 893); however, the study failed to control for maternal age and smoking status, and maternal diazepam exposure. 36 The same study found no increased risk of spontaneous abortion, pre-term birth, Down’s syndrome, or other chromosomal abnormalities for offspring paternally exposed to diazepam, compared with unexposed offspring. 36 In a small cohort study, infants paternally exposed to ASMs (n=22) were reported to have normal birth length. 28
This systematic review is timely in view of the 2024 public release by the EMA 25 and the MHRA 38 of the main results of a meta-analysis of data from a retrospective observational study on birth outcomes in children born to men taking valproate, lamotrigine or levetiracetam at about the time of conception. The study, based on data from multiple registry databases in Denmark, Sweden, and Norway, is yet to be published after peer review and therefore could not be included in our analysis. However, an extended abstract has been made available recently on the EMA website. 26 The findings of the study indicated that paternal exposure to valproate in the 3 months before conception was associated in the offspring with a pooled adjusted HR of 1.50 (95% CI: 1.09 to 2.07) for neurodevelopmental disorders (a composite outcome comprising intellectual disabilities, ASD and ADHD) compared with exposure to lamotrigine or levetiracetam. The adjusted cumulative risk of neurodevelopmental disorders was estimated to be ‘around 5%’ in the valproate-exposed cohort compared with ‘around 3%’ in the lamotrigine- and levetiracetam-exposed cohorts. 25 No difference between exposure groups was found for congenital malformations in a pooled analysis across Denmark and Norway (crude pooled OR=0.81, 95% CI: 0.48 to 1.36). 26 Overall, the study had several major methodological limitations, largely related to inability to account for potential major confounders. In particular, the analysis could not control for the paternal condition for which the treatments were prescribed, even though epilepsy was more common in the valproate cohort (57–70%, depending on country) than in the combined levetiracetam/lamotrigine cohort (41–59%). Likewise, the study did not control for the type of epilepsy, which probably differed across exposure groups and may have influenced neurodevelopmental risks. There was also considerable heterogeneity in datasets and outcomes across countries, and across treatment groups. Importantly, duration of follow-up of exposed offspring differed across ASM groups, being longer for valproate. In Sweden and Denmark, the proportion of offspring followed up for >8 years was almost twice as large in the valproate group compared with the lamotrigine/levetiracetam group (Sweden: 41.8% vs 23.3%; Denmark: 74.3% vs 40.2%). Since the probability of identifying a neurodevelopmental disorder, including ASD, is age-dependent and is likely to be highest when children start school, this may have biased the risk estimate against the valproate-exposed group. The EMA’s public release and the study abstract do acknowledge the study limitations, including the inability to identify the type(s) of neurodevelopmental disorders at putatively increased risk, and emphasise that because of potential confounders a cause-effect relationship with paternal valproate exposure could not be established.
Our systematic review did not find clear evidence of an increased risk of adverse outcomes among offspring paternally exposed to ASMs. While there were some isolated unfavourable findings, these were not confirmed by other studies. Specifically, an increased prevalence of autistic traits reported at age 18 months in ASM-exposed offspring was not confirmed using a more robust assessment tool at the same age, or replicated by another ASD screening tool in the same cohort at age 36 months, 33 or confirmed by other population-based studies. 30 31 34 Other signals included a report of abnormal personal-social skills at age 18 months in the same cohort of ASM-exposed offspring with autistic traits, 33 an increased risk of SGA following paternal exposure to diazepam that was likely confounded by maternal factors, 36 and an increased risk of birth defects reported in a study that was hampered by combining minor and major malformations 32 and was not replicated by other investigations. 28–33 36 37 While nothing especially alarming emerges from this review, only a few studies were included and some of these had a relatively small sample size and therefore low power to detect treatment effects. Moreover, many studies combined ASM exposures together, precluding detailed analysis of outcomes associated with individual ASMs. Of note, risks associated with paternal valproate exposure were investigated by only three studies with respect to risk of congenital malformations, 30 , 31 32 and by only two studies with respect to risk of neurodevelopmental disorders. 30 31 Of note, the latest population-based study from Denmark, published after the release of the MHRA restrictions, focused specifically on neurodevelopmental disorders after paternal valproate exposure compared with unexposed controls, and found no significant increase in risk, with the upper limit of the 95% CI of the adjusted HR being below the risk estimate of the EMA-commissioned study. 30
There were several methodological weaknesses identified by our review. In addition to failure by most studies to provide data on risks associated with specific ASMs, only one study 30 assessed the influence of paternal ASM dose, which is known to affect the risk of MCMs and adverse neurodevelopmental outcomes in offspring of ASM-treated mothers. 39 40 Moreover, many studies neglected to control for confounders, such as age, educational attainment, exposure to other teratogens, relevant medical and psychiatric history, and other factors. There was heterogeneity in the length of follow-up for some studies, particularly those aimed at investigating neurodevelopmental outcomes, with some conducted during infancy 35 or early childhood 29 33 and others extending follow-up into adolescence. 31 34 Furthermore, there was heterogeneity in how neurodevelopmental disorders were measured and defined, with some studies investigating the presence of specific traits, 33 35 and others quantifying the risk of diagnosis of neurodevelopmental disorders at a population level. 30 31 34 For studies aimed at investigating the risk of MCMs, there was variability in how congenital anomalies were measured, with some applying stringent classification systems (eg, the European Surveillance of Congenital Anomalies (EUROCAT), and the International Classification of Diseases (ICD)-10) for the definition of MCMs, 30–32 41 whereas another measured the presence of any defect with no distinction made between major or minor anomalies. 32 This variability in the definition and measurement of both MCMs and neurodevelopmental outcomes hindered data synthesis and prevented meta-analysis for this review.
Evaluating second generation adverse effects of medications is methodologically challenging because these effects can only be investigated in observational studies. These studies are subject to bias from unmeasured potential confounding variables, and therefore an understanding of risks requires a clear signal across multiple investigations, which is precisely what is lacking based on the evidence reviewed. To date, the only signal of concern was raised by the EMA-commissioned study which, as discussed above, could be affected by major confounders. The European regulator acknowledged that available data are inconclusive in establishing cause-effect relationships, but recommended that doctors should inform males taking valproate about the potential risks, discuss the possibility of effective contraception, and review regularly the need for valproate therapy particularly for individuals planning fatherhood. 25 The MHRA took a more restrictive approach, apparently influenced by preclinical data on valproate reproductive toxicity and potential association with reduced fertility, and determined that, as from 31 January 2024 ‘valproate must not be started in new patients (male or female) younger than 55 years unless two specialists independently consider and document that there is no other effective or tolerated treatment, or there are compelling reasons why the reproductive risks do not apply’. 38 The wisdom of the UK regulatory changes has been questioned 42 because restricting the use of valproate could result in prescription of a less effective medication, particularly in individuals with generalised epilepsies where valproate is the most effective ASM. 43 Avoidance of valproate or its delayed introduction in individuals that require this medication for seizure control is likely to lead to an increased risk of morbidity and mortality, including an increased risk of sudden unexpected death in epilepsy (SUDEP). A significant increase in maternal SUDEP has already been shown in the UK during a period in which the stricter guidelines for prescribing valproate in females were introduced. 44 There is also a risk of generating anxiety among valproate-treated men with epilepsy, ultimately leading to poor medication adherence and breakthrough seizures. In view of the findings of this systematic review, particularly the reassuring results from the recent large population-based study from Denmark, 30 the MHRA restrictions regarding the use of valproate in men should be reappraised and potentially revised.
While the findings summarised in our systematic review are overall reassuring for males taking ASMs including valproate, it is clear that the potential reproductive implications of ASM exposure in males remain an under-investigated area of research that should be prioritised over the next decade. Future research should aim at replicating the methodology of maternal ASM studies and employ detailed clinical evaluations of offspring paternally exposed to different ASM monotherapies through implementation of large prospective investigations. Some of these studies could use the infrastructure already established for prospective pregnancy registries of women taking ASMs and begin to enrol males on ASMs to assemble a well-characterised cohort of offspring outcome data.
Patient consent for publication.
Not applicable.
Supplementary data.
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
PP and EP are joint senior authors.
Contributors EH, PP and EP conceived and designed the systematic review. EH, GR, CBM, PP, FV, TOB and EP contributed to the conception and development of the study protocol. EH drafted the protocol and registered it on PROSPERO. EH, EP, and PP contributed to the data acquisition, analysis, and interpretation. EH is the first author and guarantor, PP is the corresponding author of the review. All authors reviewed, edited, and approved the final manuscript.
Funding EH is supported by an Australian Government Research Training Program (RTP) Scholarship. PP is supported by an Emerging Leadership Investigator Grant from the Australian National Health and Medical Research Council (APP2017651), the University of Melbourne, Monash University, the Austin Medical Research Foundation, and the Norman Beischer Medical Research Foundation.
Competing interests CBM has received conference travel support and/or speaker fees from Merck, Novartis, and Biogen. He has received research support from the National Health and Medical Research Council, Multiple Sclerosis Research Australia, the University of Melbourne, the Royal Melbourne Hospital Neuroscience Foundation, and Dementia Australia. TOB has received research support from the Epilepsy Society of Australia, National Health and Medical Research Council, Royal Melbourne Hospital Neuroscience Foundation, Sanofi-Aventis, UCB Pharma, Janssen-Cilag, Novartis, and Sci-Gen. EP received speaker’s or consultancy fees from Eisai, GRIN Therapeutics, Shackelford Pharma, Sintetica, SKL Life Science, Sun Pharma, Takeda, UCB Pharma and Xenon Pharma and royalties from Wiley, Elsevier, and Wolters Kluwers. He is also on the board of EURAP-International Registry of Antiepileptic Drugs and Pregnancy, a non-profit organization which received financial support from Accord, Angelini, Bial, EcuPharma, Eisai, Glenmark, GW Pharma, GlaxoSmithKline, Sanofi, SF Group, Teva, UCB, and Zentiva. PP has received speaker honoraria or consultancy fees to his institution from Chiesi, Eisai, LivaNova, Novartis, Sun Pharma, Supernus, and UCB Pharma, outside of the submitted work. He is an Associate Editor for Epilepsia Open. He is also on the board of EURAP-International Registry of Antiepileptic Drugs and Pregnancy, a non-profit organization which received financial support from Accord, Angelini, Bial, EcuPharma, Eisai, Glenmark, GW Pharma, GlaxoSmithKline, Sanofi, SF Group, Teva, UCB, and Zentiva. GR has received speaker honoraria from Liva Nova. FV has received research support for the Australian Pregnancy Register from the Epilepsy Society of Australia, National Health and Medical Research Council, Royal Melbourne Hospital Neuroscience Foundation, Epilepsy Action Australia, Sanofi-Aventis, UCB Pharma, Janssen-Cilag, Novartis, and Sci-Gen. He is also on the board of EURAP-International Registry of Antiepileptic Drugs and Pregnancy, a non-profit organization which received financial support from Accord, Angelini, Bial, EcuPharma, Eisai, Glenmark, GW Pharma, GlaxoSmithKline, Sanofi, SF Group, Teva, UCB, and Zentiva. EH does not have any conflicts of interest to disclose.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
IMAGES
VIDEO
COMMENTS
This infographic lists 6 differences to help you distinguish between the background of a study and a literature review. Feel free to download a PDF version of this infographic and use it as a handy reference. How to write the background of your study. 8 Dos and 8 don'ts of writing an engaging study background.
The study background and literature review serve slightly different purposes; the study background emphasizes the significance of THE study, whereas the review of literature emphasizes advancement in the field by conducting a critical analysis of existing literature. It should be noted that a literature review also identifies gaps in the ...
Literature review is a crucial component of research writing, providing a solid background for a research paper's investigation. The aim is to keep professionals up to date by providing an understanding of ongoing developments within a specific field, including research methods, and experimental techniques used in that field, and present that ...
Examples of literature reviews. Step 1 - Search for relevant literature. Step 2 - Evaluate and select sources. Step 3 - Identify themes, debates, and gaps. Step 4 - Outline your literature review's structure. Step 5 - Write your literature review.
A literature review is an integrated analysis-- not just a summary-- of scholarly writings and other relevant evidence related directly to your research question.That is, it represents a synthesis of the evidence that provides background information on your topic and shows a association between the evidence and your research question.
This is generally referred to as the "literature review," "theoretical framework," or "research background." However, for a literature review to become a proper research methodology, as with any other research, follow proper steps need to be followed and action taken to ensure the review is accurate, precise, and trustworthy.
A literature or narrative review is a comprehensive review and analysis of the published literature on a specific topic or research question. The literature that is reviewed contains: books, articles, academic articles, conference proceedings, association papers, and dissertations. ... It provides background and context, and shows how your ...
Here are the steps to write the background of the study in a research paper: Identify the research problem: Start by identifying the research problem that your study aims to address. This can be a particular issue, a gap in the literature, or a need for further investigation. Conduct a literature review: Conduct a thorough literature review to ...
Background Information vs. the Literature Review. Incorporating background information into the introduction is intended to provide the reader with critical information about the topic being studied, such as, highlighting and expanding upon foundational studies conducted in the past, describing important historical events that inform why and in ...
Writing a literature review requires a range of skills to gather, sort, evaluate and summarise peer-reviewed published data into a relevant and informative unbiased narrative. Digital access to research papers, academic texts, review articles, reference databases and public data sets are all sources of information that are available to enrich ...
Many authors find it difficult to discern the difference between the literature review and the study background. The literature review section should follow the background section, as the second section of your manuscript/thesis. This section basically supports the background section by providing evidence for the proposed hypothesis.
Contextualization: They provide background on your research topic, helping to situate your work within the broader field. ... A Literature Review Matrix is a powerful tool that helps you organize and evaluate the sources you've gathered for your literature review. Think of it as a structured table that allows you to visually track key details ...
Literature reviews can take two major forms. The most prevalent one is the "literature review" or "background" section within a journal paper or a chapter in a graduate thesis. This section synthesizes the extant literature and usually identifies the gaps in knowledge that the empirical study addresses (Sylvester, Tate, & Johnstone, 2013).
Literature review is usually longer and it can be a whole work/article or a part of a thesis. Background section is usually short and the first part of research article. For literature review you should thoroughly go through all available studies, assess the important findings in them, discuss them and find some relevance for them.
A literature review examines current and relevant research associated with the study question. It is comprehensive, critical, and purposeful. A theoretical framework illuminates the phenomenon of study and the corresponding assumptions adopted by the researcher. Frameworks can take on different orientations.
The structure of a background study in a research paper generally follows a logical sequence to provide context, justification, and an understanding of the research problem. It includes an introduction, general background, literature review, rationale, objectives, scope and limitations, significance of the study and the research hypothesis ...
Infographic: 5 Key differences between the background and literature review sections of a research paper. Marisha Fonseca. An editor at heart and perfectionist by disposition, providing solutions for journals, publishers, and universities in areas like alt-text writing and publication consultancy.
These sections serve to establish a scholarly basis for the research or discussion within the paper. In a standard 8000-word journal article, the literature review section typically spans between 750 and 1250 words. The first few sentences or the first paragraph within this section often serve as an introduction.
Research background is written after the literature review. Therefore, literature review has to be the first and the longest stage in the research process, even before the formulation of research aims and objectives, right after the selection of the research area. Once the research area is selected, the literature review is commenced in order ...
A literature review and a theoretical framework are not the same thing and cannot be used interchangeably. While a theoretical framework describes the theoretical underpinnings of your work, a literature review critically evaluates existing research relating to your topic. You'll likely need both in your dissertation.
background of a study may include an extensive literature review, analysis of the current trend in the related topic, identify any literature gap and more importantly a background study justifies ...
Background and Literature Review Download book PDF. Download book EPUB ... As highlighted in the literature review, there remains a need for research and an applicable method to reduce the volume of digital forensic data for analysis for evidence and intelligence. Technology is rapidly increasing, and is increasingly used by consumers, business ...
1. Chapter 2 - Research Background and Literature Review. This chapter is divided into two parts. The first part discusses the research background and. the second part provides a comprehensive ...
2 Background and Related Work 2.1 DLT. The emergence of DLT marks a shift in data management from centralized systems to decentralized solutions. ... Our literature review alluded to six use cases in healthcare for which DLT is applied and four purposes, which motivate the utilization of DLT. For each purpose, we identified different DLT ...
A Systematic Scoping Review. Using the framework developed by Arksey and O'Malley (), a systematic scoping review methodology was used to identify the available research literature on the disclosure of child sexual abuse.To clarify the use of the term 'systematic' in the context of a scoping review, we adopted a methodologically sound process for searching the literature to scope the ...
The rarity of the described conditions challenged the team to search for relevant examples in the existing scientific literature in order to discuss the phenomena in a broader sense. Thus, a systemic review of the current literature about anatomical variations of origin of carotid arteries was also performed according to the PRISMA methodology.
Background: Lung resection is the primary treatment option for many patients with lung cancer; however, it is a high-risk surgery with many potentially lethal perioperative complications. The aim of this review is to examine the capability of forced expiratory volume in one second (FEV1), diffusing capacity of the lung for carbon monoxide (DLCO), maximal oxygen uptake in exercise (VO2max), and ...
Introduction and background. Acute coronary syndrome (ACS) represents a common clinical manifestation of cardiovascular disease (CVD), which annually results in a large number of hospital admissions and emergency department consultations around the world [].Despite advances in reperfusion strategies and improvements in supportive pharmacological treatments, people with acute myocardial ...
Background Rare diseases (RD) like akute porphyrias (APs) present a particular challenge for emergency physicians (EP), as their acute symptoms are usually nonspecific and resemble common clinical presentations. This is compounded by low awareness and limited training of EP regarding RD, often leading to patients with RD being discharged without an accurate diagnosis. Consequently, despite the ...
Background Concerns have recently been raised about risks to the fetus resulting from paternal exposure to antiseizure medications (ASMs). To address these concerns, we conducted a systematic review of the literature to assess neurodevelopmental and anatomical outcomes in offspring born to fathers taking ASMs at the time of conception. Methods Electronic searches of MEDLINE, PsycINFO, and ...